<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TACROLIMUS- tacrolimus capsule </strong><br>Dr. Reddy's Laboratories Limited<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use</span><span class="Bold"> tacrolimus safely and effectively. See full prescribing information for tacrolimus.</span><span class="Bold"><br>TACROLIMUS capsules USP, for oral use</span><span class="Bold"><br>Initial U.S. Approval: 1994</span>
</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING: MALIGNANCIES AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></span><span class="Bold"></span>
</h1>
<h1 class="Warning">
<span class="Bold Italics">See full prescribing information for complete boxed warning</span><span class="Bold"></span>
</h1>
<ul>
<li>
<span class="Bold">Increased risk of development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies, particularly of the skin, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> </span><span class="Bold"><a href="#_c1430800-6a47-a6a5-a2eb-d70663158c0e">(5.2)</a></span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Increased susceptibility to bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (</span><span class="Bold"><a href="#_02669390-2e85-f61f-7aac-bc927dd1f4e7">5.3</a>, <a href="#_44b3d223-cdaa-0055-c648-e14294ed0028">5.4</a></span>, <span class="Bold"><a href="#_efae5194-9a5b-ac74-3462-14bfa59bb652">5.5</a></span><span class="Bold">)</span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe tacrolimus </span><a href="#_c9a8b96a-2d97-8561-b897-a6f8d0da4973">(</a><span class="Bold"><a href="#_c9a8b96a-2d97-8561-b897-a6f8d0da4973">5.1)</a></span>
</li>
</ul>
</div></div>
<div><div></div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING: MALIGNANCIES AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></span><span class="Bold"></span>
</h1>
<h1 class="Warning">
<span class="Bold Italics">See full prescribing information for complete boxed warning</span><span class="Bold"></span>
</h1>
<ul>
<li>
<span class="Bold">Increased risk of development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies, particularly of the skin, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> </span><span class="Bold"><a href="#_c1430800-6a47-a6a5-a2eb-d70663158c0e">(5.2)</a></span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Increased susceptibility to bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (</span><span class="Bold"><a href="#_02669390-2e85-f61f-7aac-bc927dd1f4e7">5.3</a>, <a href="#_44b3d223-cdaa-0055-c648-e14294ed0028">5.4</a></span>, <span class="Bold"><a href="#_efae5194-9a5b-ac74-3462-14bfa59bb652">5.5</a></span><span class="Bold">)</span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe tacrolimus </span><a href="#_c9a8b96a-2d97-8561-b897-a6f8d0da4973">(</a><span class="Bold"><a href="#_c9a8b96a-2d97-8561-b897-a6f8d0da4973">5.1)</a></span>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Tacrolimus capsule is a calcineurin-inhibitor immunosuppressant indicated for </p>
<ul>
<li>Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney  or heart transplants (<a href="#_a506de58-027a-4a29-4caa-c53c4fea5085">1.1</a>, <a href="#_e27f230f-1d3e-6a3e-cbd6-317ac577a130">1.2</a>, <a href="#_f0d23faa-f864-dd79-0fac-31e91759bbad">1.3</a>)</li>
<li>Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) (<a href="#_a506de58-027a-4a29-4caa-c53c4fea5085">1.1</a>, <a href="#_e27f230f-1d3e-6a3e-cbd6-317ac577a130">1.2</a>, <a href="#_f0d23faa-f864-dd79-0fac-31e91759bbad">1.3</a>)</li>
<li>Limitations of Use (<a href="#_4cfbf8db-143b-728a-cdf8-85eeba93f856">1.4</a>):<ul>
<li>Do not use simultaneously with cyclosporine</li>
<li>Intravenous use reserved for patients who can not tolerate capsules orally</li>
<li>Use with sirolimus is not recommended in liver  and heart transplant; use with sirolimus in kidney transplant has not been established<span class="Bold"></span>
</li>
</ul>
<span class="Bold"></span>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Summary of Initial Oral Dosage Recommendation and Observed Whole Blood Trough Concentrations (<a href="#_c727e851-a3c1-9956-661d-4f6786df4434">2.1</a>, <a href="#_3a7605f6-5634-6ab3-4d4c-1279ce614f23">2.2</a>).  </p>
<table border="1" cellpadding="0" cellspacing="0"><tbody class="Headless">
<tr class="First">
<td valign="top"><span class="Bold">Patient Population </span></td>
<td valign="top">
<span class="Bold">Recommended Initial Oral </span><span class="Bold">Dosage (two divided doses every 12 hours) </span>
</td>
<td valign="top"><span class="Bold">Observed Whole Blood Trough Concentrations </span></td>
</tr>
<tr>
<td valign="top">Adult Kidney transplant In combination with azathioprine  <br>In combination with MMF/IL-2 receptor antagonist </td>
<td valign="top"> 0.2 mg/kg/day   <br><br>0.1 mg/kg/day</td>
<td valign="top">month 1 to 3:7  to 20 ng/mL<br>month 4 to 12:5 to 15 ng/mL<br>month 1 to 12: 4 to11 ng/mL</td>
</tr>
<tr>
<td valign="top">Adult Liver transplant <br>Pediatric Liver transplant </td>
<td valign="top">0.10  to 0.15 mg/kg/day <br>0.15 to 0.20 mg/kg/day </td>
<td valign="top">month 1 to 12: 5 to 20 ng/mL <br>month 1 to 12: 5 to 20 ng/mL </td>
</tr>
<tr class="Last">
<td valign="top">Adult Heart transplant</td>
<td valign="top">0.075 mg/kg/day</td>
<td valign="top">month 1 to 3: 10 to 20 ng/mL month ≥4:  5 to 15 ng/mL</td>
</tr>
</tbody></table>
<br><ul>
<li>Careful and frequent monitoring of tacrolimus trough concentrations is recommended; Black patients may require higher doses in order to achieve comparable trough concentrations <a href="#_c727e851-a3c1-9956-661d-4f6786df4434">(2.1)</a>
</li>
<li>Hepatic/Renal impaired patients should receive doses at the lowest value of the recommended initial oral dosing range (<a href="#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4">2.3</a>, <a href="#_59b20539-7308-91d8-2ed0-31decab6ad6c">2.4</a>)</li>
<li>Administer capsules consistently with or without food; do not drink grapefruit juice (<a href="#_f4e10115-ade6-2ded-a674-e5294ba195be">2.5</a>, <a href="#_ae530d6d-766e-6741-d24b-eb43b2d6d14e">7.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Capsules: 0.5 mg, 1 mg and 5 mg <a href="#DOSAGE_FORMS_AND_STRENGTHS">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to tacrolimus or HCO-60 (polyoxyl 60 hydrogenated castor oil) <a href="#CONTRAINDICATIONS">(4)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies: Risk of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>, including <span class="product-label-link" type="condition" conceptid="42872948" conceptname="Post transplant lymphoproliferative disorder">post transplant lymphoproliferative disorder</span> (PLTD); appears related to intensity and duration of use. Avoid prolonged exposure to UV light and sunlight <a href="#_c1430800-6a47-a6a5-a2eb-d70663158c0e">(5.2)</a>
</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: Increased risk of bacterial, viral, fungal and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>: combination <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> should be used with caution <a href="#_02669390-2e85-f61f-7aac-bc927dd1f4e7">(5.3)</a>
</li>
<li>Polyoma Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Serious, sometimes fatal outcomes, including polyoma virus-associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> (PVAN), mostly due to BK virus, and JC virus-associated <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML); consider reducing <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> <a href="#_44b3d223-cdaa-0055-c648-e14294ed0028">(5.4)</a>
</li>
<li>Cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Increased risk of <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> and disease; consider reducing <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> <a href="#_efae5194-9a5b-ac74-3462-14bfa59bb652">(5.5)</a>
</li>
<li>New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant: Monitor blood glucose <a href="#_773498b8-5185-3ab8-d970-77c806ec54bd">(5.6)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>: Acute and/or chronic; reduce the dose; use caution with other nephrotoxic drugs <a href="#_646586f3-4314-3d61-f221-3d0e7562ad4f">(5.7)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>: Risk of Posterior Reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> Syndrome, monitor for neurologic abnormalities; reduce or discontinue tacrolimus and other immunosuppressants <a href="#_6c58d880-0731-32f6-fc2f-48b62ea0f34c">(5.8)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>: Monitor serum potassium levels. Careful consideration should be given prior to use of other agents also associated with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <a href="#_387963e5-2598-e73d-af6c-19d0dd2730e8">(5.9)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: May require antihypertensive therapy. Monitor relevant drug-drug interactions <a href="#_705070f6-9650-af7d-b658-b66fead6566c">(5.10)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> with IV formulation: Observe patients receiving tacrolimus injection for signs and symptoms of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> <a href="#_21503048-1fac-0eb3-da71-b995151e9c67">(5.11)</a>
</li>
<li>Use with Sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions <a href="#_e6fb816e-da0b-9c41-17be-6995a0dade06">(5.12)</a>
</li>
<li>Myocardial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">Hypertrophy</span>: Consider dosage reduction or discontinuation <a href="#_d029624c-cc25-d6ca-5e0d-f793ae29f66a">(5.15)</a>
</li>
<li>Immunizations: Use of live vaccines should be avoided <a href="#_fef74a58-2fff-8264-0a04-7917ca25611d">(5.16)</a>
</li>
<li>Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span>: Discontinuation should be considered <a href="#_c8082f53-9883-3ed8-8a77-6b64f1d2bd71">(5.17)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>Kidney Transplant: The most common adverse reactions ( ≥ 30%) were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, abnormal renal function, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a>
</li>
<li>Liver Transplant: The most common adverse reactions (≥ 40%) were <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, abnormal renal function, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a>
</li>
<li>Heart Transplant: The most common adverse reactions ( ≥ 15%) were abnormal renal function, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span> <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a>
</li>
</ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or </span><span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Mycophenolic Acid Products: Can increase MPA exposure after crossover from cyclosporine to tacrolimus; monitor for MPA-related adverse reactions and adjust MMF or MPA-dose as needed <a href="#_b992fb27-d2dc-9813-f898-40cb4c49a412">(7.1)</a>
</li>
<li>Nelfinavir and Grapefruit Juice: Increased tacrolimus concentrations via CYP3A inhibition; avoid concomitant use (<a href="#_ae530d6d-766e-6741-d24b-eb43b2d6d14e">7.2</a>, <a href="#_3447c8d3-0e24-1461-e6b5-a4f7a84bd9d7">7.3</a>)</li>
<li>CYP3A Inhibitors: Increased tacrolimus concentrations; monitor concentrations and adjust tacrolimus dose as needed with concomitant use (<a href="#_dc63967f-8dce-04c0-f4a6-b5609d0483f7">5.13</a>, <a href="#_3447c8d3-0e24-1461-e6b5-a4f7a84bd9d7">7.3</a>, <a href="#_ff7f9ee1-7369-84a6-6e82-2f2ed520c272">7.4</a>, <a href="#_41c0b559-2679-99f5-4217-e0570466e7a5">7.5</a>, <a href="#_3c8ae943-bac2-4d95-a42b-5cd0e78815b2">7.6</a>)</li>
<li>CYP3A4 Inducers: Decreased tacrolimus concentrations; monitor concentrations and adjust tacrolimus dose as needed with concomitant use (<a href="#_dc63967f-8dce-04c0-f4a6-b5609d0483f7">5.13</a>, <a href="#_36fabc49-0730-85f8-8f0e-c2b8c8713515">7.7</a>, <a href="#_8ad9a415-701e-7800-3903-e16da4a8bf9c">7.8</a>, <a href="#_35b21cda-e072-788a-1538-c4874e89de0d">7.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Based on animal data may cause fetal harm. Use only if the potential benefit justifies the risk <a href="#PREGNANCY">(8.1)</a>
</li>
<li>Nursing Mothers: Discontinue nursing taking into consideration importance of drug to mother <a href="#NURSING_MOTHERS">(8.3)</a>
</li>
<li>Hepatic/Renal impaired patients: Administer at the lower end of the recommended starting dose. Monitor renal function in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (<a href="#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4">2.3,</a><a href="#_59b20539-7308-91d8-2ed0-31decab6ad6c">2.4</a>, <a href="#_832ba428-c534-9139-0837-d637e38193bc">8.6</a>, <a href="#_e0570a1e-c88a-34a9-de3e-66b1375da927">8.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1 Prophylaxis of Organ Rejection in Kidney Transplant</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2 Prophylaxis of Organ Rejection in Liver Transplant</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Prophylaxis of Organ Rejection in Heart Transplant</a></h2>
<h2><a href="#section-1.4" class="toc"><span class="Bold">1.4 Limitations of Use</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 Dosage in Adult Kidney, Liver. or Heart Transplant Patients</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2 Dosage in Pediatric Liver Transplant Patients</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3 Dosage Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4 Dosage Adjustments in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h2><a href="#section-2.5" class="toc"><span class="Bold">2.5 Administration Instructions</span></a></h2>
<h2><a href="#section-2.6" class="toc"><span class="Bold">2.6 Therapeutic Drug Monitoring</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 Management of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Polyoma Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 Cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span><span class="Bold"></span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant</span><span class="Bold"></span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8 <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.10 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-5.11" class="toc"><span class="Bold">5.11 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> with Tacrolimus Injection</span><span class="Bold"></span></a></h2>
<h2><a href="#section-5.12" class="toc"><span class="Bold">5.12 Use with Sirolimus</span></a></h2>
<h2><a href="#section-5.13" class="toc"><span class="Bold">5.13 Use with CYP3A4 Inhibitors and Inducers</span></a></h2>
<h2><a href="#section-5.14" class="toc"><span class="Bold">5.14 QT Prolongation</span></a></h2>
<h2><a href="#section-5.15" class="toc"><span class="Bold">5.15 Myocardial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">Hypertrophy</span></span></a></h2>
<h2><a href="#section-5.16" class="toc"><span class="Bold">5.16 Immunizations</span></a></h2>
<h2><a href="#section-5.17" class="toc"><span class="Bold">5.17 Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span></span></a></h2>
<h2><a href="#section-5.18" class="toc"><span class="Bold">5.18 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Studies Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 Postmarketing Adverse Reactions</span></a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 Mycophenolic Acid Products</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2 Grapefruit Juice</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.3 Protease Inhibitors</span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.4 Antifungal Agents</span></a></h2>
<h2><a href="#section-7.5" class="toc"><span class="Bold">7.5 Calcium Channel Blockers</span></a></h2>
<h2><a href="#section-7.6" class="toc"><span class="Bold">7.6 Antibacterials</span></a></h2>
<h2><a href="#section-7.7" class="toc"><span class="Bold">7.7 Antimycobacterials</span></a></h2>
<h2><a href="#section-7.8" class="toc"><span class="Bold">7.8 Anticonvulsants</span></a></h2>
<h2><a href="#section-7.9" class="toc"><span class="Bold">7.9 St. John’s Wort (Hypericum perforatum)</span></a></h2>
<h2><a href="#section-7.10" class="toc"><span class="Bold">7.10 Gastric Acid Suppressors/Neutralizers</span></a></h2>
<h2><a href="#section-7.11" class="toc"><span class="Bold">7.11 Others</span></a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.6 Use in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.7 Use in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1 Kidney Transplantation</span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2 Liver Transplantation</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Heart Transplantation</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc"><span class="Bold">16.1 Tacrolimus Capsules </span></a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc"><span class="Bold">17.1 Administration</span></a></h2>
<h2><a href="#section-15.2" class="toc"><span class="Bold">17.2 Development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies</span></a></h2>
<h2><a href="#section-15.3" class="toc"><span class="Bold">17.3 Increased Risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></a></h2>
<h2><a href="#section-15.4" class="toc"><span class="Bold">17.4 New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant</span></a></h2>
<h2><a href="#section-15.5" class="toc"><span class="Bold">17.5 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></span></a></h2>
<h2><a href="#section-15.6" class="toc"><span class="Bold">17.6 <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></span></a></h2>
<h2><a href="#section-15.7" class="toc"><span class="Bold">17.7 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></a></h2>
<h2><a href="#section-15.8" class="toc"><span class="Bold">17.8 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-15.9" class="toc"><span class="Bold">17.9 Drug Interactions</span></a></h2>
<h2><a href="#section-15.10" class="toc"><span class="Bold">17.10 Pregnant Women and Nursing Mothers</span></a></h2>
<h2><a href="#section-15.11" class="toc"><span class="Bold">17.11 Immunizations</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Warning">
<a name="BOXED_WARNING"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">BOXED WARNING – MALIGNANCIES AND SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></span><span class="Bold"></span></p>
<ul>
<li>
<span class="Bold">Increased risk of development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and other malignancies, particularly of the skin, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> [see </span><span class="Bold">Warnings and Precautions </span><span class="Bold"><a href="#_c1430800-6a47-a6a5-a2eb-d70663158c0e">(5.2)</a></span><span class="Bold">]</span><span class="Bold">.</span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Increased susceptibility to bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> [see </span><span class="Bold">Warnings and Precautions </span>(<span class="Bold"><a href="#_02669390-2e85-f61f-7aac-bc927dd1f4e7">5.3</a>, <a href="#_44b3d223-cdaa-0055-c648-e14294ed0028">5.4</a>, <a href="#_efae5194-9a5b-ac74-3462-14bfa59bb652">5.5</a></span>) <span class="Bold">]</span><span class="Bold">.</span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe tacrolimus. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions </span><span class="Bold"><a href="#_c9a8b96a-2d97-8561-b897-a6f8d0da4973">(5.1)</a></span><span class="Bold">].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS_AND_USAGE"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_a506de58-027a-4a29-4caa-c53c4fea5085"></a><a name="section-1.1"></a><p></p>
<h2><span class="Bold">1.1 Prophylaxis of Organ Rejection in Kidney Transplant</span></h2>
<p class="First">Tacrolimus capsules are indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney transplants. It is recommended that tacrolimus capsules be used concomitantly with azathioprine or mycophenolate mofetil (MMF) and adrenal corticosteroids [see <span class="Bold">Clinical Studies </span><span class="Bold"><a href="#_df213488-e1ee-4264-95f9-0422aedfd287">(14.1)</a></span>]. Therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules [see <span class="Bold">Dosage and Administration </span><span class="Bold"><a href="#_4c11e474-0cf1-738d-70b3-aad07f9c206c">(2.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_e27f230f-1d3e-6a3e-cbd6-317ac577a130"></a><a name="section-1.2"></a><p></p>
<h2><span class="Bold">1.2 Prophylaxis of Organ Rejection in Liver Transplant</span></h2>
<p class="First">Tacrolimus capsules are indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants. It is recommended that tacrolimus capsules be used concomitantly with adrenal corticosteroids [see <span class="Bold">Clinical Studies </span><span class="Bold"><a href="#_512f934b-b9b0-4ace-8e47-e0cb63709432">(14.2)</a></span>]. Therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules [see <span class="Bold">Dosage and Administration </span><span class="Bold"><a href="#_4c11e474-0cf1-738d-70b3-aad07f9c206c">(2.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_f0d23faa-f864-dd79-0fac-31e91759bbad"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Prophylaxis of Organ Rejection in Heart Transplant</h2>
<p class="First">Tacrolimus capsules are indicated for the prophylaxis of organ rejection in patients receiving allogeneic heart transplants. It is recommended that tacrolimus capsules be used concomitantly with azathioprine or mycophenolate mofetil (MMF) and adrenal corticosteroids [see <span class="Bold">Clinical Studies </span><span class="Bold"><a href="#_ffaafd59-ab63-c1bc-003d-3f7ccb173898">(14.3)</a></span>]. Therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules[see <span class="Bold">Dosage and Administration </span><span class="Bold"><a href="#_4c11e474-0cf1-738d-70b3-aad07f9c206c">(2.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_4cfbf8db-143b-728a-cdf8-85eeba93f856"></a><a name="section-1.4"></a><p></p>
<h2><span class="Bold">1.4 Limitations of Use</span></h2>
<p class="First">Tacrolimus capsules should not be used simultaneously with cyclosporine [see <span class="Bold">Dosage and Administration </span><span class="Bold"><a href="#_f4e10115-ade6-2ded-a674-e5294ba195be">(2.5)</a></span>].</p>
<p>Use with sirolimus is not recommended in liver and heart transplant. The safety and efficacy of tacrolimus capsules with sirolimus has not been established in kidney transplant [see <span class="Bold">Warnings and Precautions </span><span class="Bold"><a href="#_e6fb816e-da0b-9c41-17be-6995a0dade06">(5.12)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE_AND_ADMINISTRATION"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_c727e851-a3c1-9956-661d-4f6786df4434"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 Dosage in Adult Kidney, Liver. or Heart Transplant Patients</span></h2>
<p class="First">The initial oral dosage recommendations for adult patients with kidney, liver, or heart transplants along with recommendations for whole blood trough concentrations are shown in Table 1. The initial dose of tacrolimus capsules should be administered no sooner than 6 hours after transplantation in the liver and heart transplant patients. In kidney transplant patients, the initial dose of tacrolimus capsules may be administered within 24 hours of transplantation, but should be delayed until renal function has recovered. For blood concentration monitoring details see <span class="Bold">Dosage and Administration (<a href="#_4c11e474-0cf1-738d-70b3-aad07f9c206c">2.6</a>).</span></p>
<p><span class="Bold">Table 1. Summary of Initial Oral Dosage Recommendations and Observed Whole Blood Trough Concentrations in Adults</span></p>
<table border="1" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="First">
<td valign="top"><span class="Bold">Patient Population </span></td>
<td valign="bottom">
<span class="Bold">Recommended Tacrolimus Initial Oral Dosage </span>Note: daily doses should be administered as two divided doses, every 12 hours </td>
<td valign="top"><span class="Bold">Observed Tacrolimus Whole Blood Trough Concentrations </span></td>
</tr>
<tr>
<td valign="top">Adult kidney transplant patients <br>In combination with azathioprine   <br>In combination with MMF/IL-2 receptor antagonist <span class="Sup">a</span>
</td>
<td valign="top">  <br><br>0.2 mg/kg/day   <br><br>0.1 mg/kg/day</td>
<td valign="top">
<br><br>month 1 to 3: 7 to 20 ng/mL<br>month 4 to 12: 5 to 15 ng/mL <br>month 1 to 12: 4 to 11 ng/mL</td>
</tr>
<tr>
<td>Adult liver transplant patients </td>
<td>0.10 to 0.15 mg/kg/day </td>
<td>month 1 to 12: 5 to 20 ng/mL </td>
</tr>
<tr class="Last">
<td>Adult heart transplant patients</td>
<td>0.075 mg/kg/day</td>
<td>month 1 to 3: 10 to 20 ng/mL <br>month ≥4: 5 to 15 ng/mL</td>
</tr>
</tbody></table>
<p>In a second smaller trial, the initial dose of tacrolimus was 0.15 to 0.2 mg/kg/day and observed tacrolimus concentrations were 6 to 16 ng/mL during month 1 to 3 and 5 to 12 ng/mL during month 4 to 12 [see<span class="Bold">Clinical Studies <a href="#_df213488-e1ee-4264-95f9-0422aedfd287">(14.1)</a></span>]. Dosing should be titrated based on clinical assessments of rejection and tolerability. Lower tacrolimus capsule dosages than the recommended initial dosage may be sufficient as maintenance therapy. Adjunct therapy with adrenal corticosteroids is recommended early post-transplant. The data in kidney transplant patients indicate that the Black patients required a higher dose to attain comparable trough concentrations compared to Caucasian patients (Table 2).<span class="Bold"></span><span class="Bold"></span></p>
<p><span class="Bold">Table 2. Comparative Dose and Trough Concentrations Based on Race</span></p>
<table border="1" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td><span class="Bold">Time After Transplant</span></td>
<td colspan="2">
<span class="Bold">Caucasian </span><br><span class="Bold">n=114</span>
</td>
<td colspan="2">
<span class="Bold">Black </span><br><span class="Bold">n=56</span>
</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top">
<span class="Bold">Dose</span><span class="Bold">(mg/kg)</span>
</td>
<td valign="top">
<span class="Bold">Trough Concentrations</span><span class="Bold">(ng/mL)</span>
</td>
<td valign="top"><span class="Bold">Dose (mg/kg)</span></td>
<td valign="top">
<span class="Bold">Trough Concentrations</span><span class="Bold">(ng/mL)</span>
</td>
</tr>
<tr>
<td align="left">Day 7 </td>
<td>0.18 </td>
<td>12.0 </td>
<td>0.23 </td>
<td>10.9 </td>
</tr>
<tr>
<td align="left">Month 1 </td>
<td>0.17 </td>
<td>12.8 </td>
<td>0.26 </td>
<td>12.9 </td>
</tr>
<tr>
<td align="left">Month 6 </td>
<td>0.14 </td>
<td>11.8 </td>
<td>0.24 </td>
<td>11.5 </td>
</tr>
<tr class="Last">
<td align="left">Month 12 </td>
<td>0.13 </td>
<td>10.1 </td>
<td>0.19 </td>
<td>11.0 </td>
</tr>
</tbody></table>
<p>Initial Dose – Injection </p>
<p>Tacrolimus injection should be used only as a continuous IV infusion and when the patient cannot tolerate oral administration of tacrolimus capsules.Tacrolimus injection should be discontinued as soon as the patient can tolerate oral administration of tacrolimus capsules, usually within 2 to 3 days. In a patient receiving an IV infusion, the first dose of oral therapy should be given 8 to 12 hours after discontinuing the IV infusion. </p>
<p>The observed trough concentrations described above pertain to oral administration of tacrolimus only; while monitoring tacrolimus concentrations in patients receiving tacrolimus injection as a continuous IV infusion may have some utility, the observed concentrations will not represent comparable exposures to those estimated by the trough concentrations observed in patients on oral therapy.  </p>
<p>The recommended starting dose of tacrolimus injection is 0.03 to 0.05 mg/kg/day in kidney and liver transplant and 0.01 mg/kg/day in heart transplant given as a continuous IV infusion. Adult patients should receive doses at the lower end of the dosing range. Concomitant adrenal corticosteroid therapy is recommended early post-transplantation.</p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have occurred with injectables containing castor oil derivatives, such as tacrolimus injection [see <span class="Bold">Warnings and Precautions <a href="#_21503048-1fac-0eb3-da71-b995151e9c67">(5.11)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_3a7605f6-5634-6ab3-4d4c-1279ce614f23"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">2.2 Dosage in Pediatric Liver Transplant Patients</span></h2>
<p class="First">The initial oral dosage recommendations for pediatric patients with liver transplants along with recommendations for whole blood trough concentrations are shown in Table 3. For blood concentration monitoring details see <span class="Bold">Dosage and Administration <a href="#_4c11e474-0cf1-738d-70b3-aad07f9c206c">(2.6)</a></span>. If necessary, pediatric patients may start on an IV dose of 0.03 to 0.05 mg/kg/day.</p>
<p><span class="Bold">Table 3. Summary of Initial Oral Dosage Recommendations and Observed Whole Blood Trough Concentrations in Children</span></p>
<p></p>
<table border="1" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless">
<tr class="First">
<td valign="top"><span class="Bold">Patient Population </span></td>
<td valign="top"><span class="Bold">Recommended Tacrolimus Initial Oral Dosage</span></td>
<td valign="top"><span class="Bold">Observed Tacrolimus Whole Blood Trough Concentrations</span></td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top">Note: daily doses should be administered as two divided doses, every 12 hours</td>
<td valign="top"> </td>
</tr>
<tr class="Last">
<td>Pediatric liver transplant patients </td>
<td>0.15 to 0.20 mg/kg/day </td>
<td>Month 1 to 12: 5 to 20 ng/mL </td>
</tr>
</tbody></table>
<p>Pediatric liver transplantation patients without pre-existing renal or hepatic dysfunction have required and tolerated higher doses than adults to achieve similar blood concentrations.</p>
<p>Experience in pediatric kidney and heart transplantation patients is limited.<span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">2.3 Dosage Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First">Due to its potential for <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, consideration should be given to dosing tacrolimus capsules at the lower end of the therapeutic dosing range in patients who have received a liver transplant and have pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Further reductions in dose below the targeted range may be required. </p>
<p>In kidney transplant patients with post-operative <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, the initial dose of tacrolimus capsules should be administered no sooner than 6 hours and within 24 hours of transplantation, but may be delayed until renal function shows evidence of recovery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_59b20539-7308-91d8-2ed0-31decab6ad6c"></a><a name="section-2.4"></a><p></p>
<h2><span class="Bold">2.4 Dosage Adjustments in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First">Due to the reduced clearance and prolonged half-life, patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child Pugh ≥ 10) may require lower doses of tacrolimus capsules. Close monitoring of blood concentrations is warranted.</p>
<p>The use of tacrolimus capsules in liver transplant recipients experiencing post-transplant <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may be associated with increased risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> related to high whole-blood concentrations of tacrolimus. These patients should be monitored closely and dosage adjustments should be considered. Some evidence suggests that lower doses should be used in these patients [see <span class="Bold">Dosage and Administration <a href="#_c727e851-a3c1-9956-661d-4f6786df4434">(2.1)</a>, Use in Specific Populations <a href="#_e0570a1e-c88a-34a9-de3e-66b1375da927">(8.7)</a> and Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_f4e10115-ade6-2ded-a674-e5294ba195be"></a><a name="section-2.5"></a><p></p>
<h2><span class="Bold">2.5 Administration Instructions</span></h2>
<p class="First">It is recommended that patients initiate oral therapy with tacrolimus capsules if possible.</p>
<p>Initial dosage and observed tacrolimus whole blood trough concentrations for adults are shown in Table 1 and for pediatrics in Table 3 [see <span class="Bold">Dosage and Administration (<a href="#_c727e851-a3c1-9956-661d-4f6786df4434">2.1</a>, <a href="#_3a7605f6-5634-6ab3-4d4c-1279ce614f23">2.2</a>)</span>]; for blood concentration monitoring details in kidney transplant patients [see <span class="Bold">Dosage and Administration <a href="#_c727e851-a3c1-9956-661d-4f6786df4434">(2.1)</a></span>].</p>
<p>It is important to take tacrolimus capsules consistently every day either with or without food because the presence and composition of food decreases the bioavailability of tacrolimus capsules [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>].</p>
<p>Patients should not eat grapefruit or drink grapefruit juice in combination with tacrolimus capsules [see <span class="Bold">Drug Interactions <a href="#_ae530d6d-766e-6741-d24b-eb43b2d6d14e">(7.2)</a></span>].</p>
<p>Tacrolimus capsules should not be used simultaneously with cyclosporine. Tacrolimus capsules or cyclosporine should be discontinued at least 24 hours before initiating the other. In the presence of elevated tacrolimus capsules or cyclosporine concentrations, dosing with the other drug usually should be further delayed.</p>
<p>In patients unable to take oral tacrolimus capsules, therapy may be initiated with tacrolimus injection as a continuous IV infusion. If IV therapy is necessary, conversion from IV to oral tacrolimus capsules is recommended as soon as oral therapy can be tolerated. This usually occurs within 2 to 3 days. In patients receiving an IV infusion, the first dose of oral therapy should be given 8 to 12 hours after discontinuing the IV infusion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_4c11e474-0cf1-738d-70b3-aad07f9c206c"></a><a name="section-2.6"></a><p></p>
<h2><span class="Bold">2.6 Therapeutic Drug Monitoring</span></h2>
<p class="First">Monitoring of tacrolimus blood concentrations in conjunction with other laboratory and clinical parameters is considered an essential aid to patient management for the evaluation of rejection, toxicity, dose adjustments and compliance. Observed whole blood trough concentrations can be found in Table 1. Factors influencing frequency of monitoring include but are not limited to hepatic or renal dysfunction, the addition or discontinuation of potentially interacting drugs and the post-transplant time. Blood concentration monitoring is not a replacement for renal and liver function monitoring and tissue biopsies. Data from clinical trials show that tacrolimus whole blood concentrations were most variable during the first week post-transplantation.</p>
<p>The relative risks of toxicity and efficacy failure are related to tacrolimus whole blood trough concentrations. Therefore, monitoring of whole blood trough concentrations is recommended to assist in the clinical evaluation of toxicity and efficacy failure.</p>
<p>Methods commonly used for the assay of tacrolimus include high performance liquid chromatography with tandem <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometric detection (HPLC/MS/MS) and immunoassays. Immunoassays may react with metabolites as well as parent compound. Therefore assay results obtained with immunoassays may have a positive bias relative to results of HPLC/MS. The bias may depend upon the specific assay and laboratory. Comparison of the concentrations in published literature to patient concentrations using the current assays must be made with detailed knowledge of the assay methods and biological matrices employed. Whole blood is the matrix of choice and specimens should be collected into tubes containing ethylene diamine tetraacetic acid (EDTA) anti-coagulant. Heparin anti-coagulation is not recommended because of the tendency to form clots on storage. Samples which are not analyzed immediately should be stored at room temperature or in a refrigerator and assayed within 7 days; see assay instructions for specifics. If samples are to be kept longer they should be deep frozen at -20° C. One study showed drug recovery &gt;90% for samples stored at -20° C for 6 months, with reduced recovery observed after 6 months.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="DOSAGE_FORMS_AND_STRENGTHS"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Tacrolimus Capsules USP, 0.5 mg are white to off white powder filled in hard gelatin capsule of size ‘4’, dark yellow opaque cap imprinted with ‘0.5 MG’ and dark yellow opaque body imprinted with ‘RDY 525’using red ink.</p>
<p>Tacrolimus Capsules USP, 1 mg are white to off white powder filled in hard gelatin capsule of size ‘4’, white opaque cap imprinted with ‘1 MG’ and white opaque body imprinted with ‘RDY 526’using red ink.</p>
<p>Tacrolimus Capsules USP, 5 mg are white to off white powder filled in hard gelatin capsule of size ‘4’, dark grayish red opaque cap imprinted with ‘5 MG’ and dark grayish red  opaque body imprinted with ‘RDY 527’ using white ink.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Tacrolimus is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tacrolimus. Tacrolimus injection is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to HCO-60 (polyoxyl 60 hydrogenated castor oil). <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> symptoms reported include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span> [see <span class="Bold">Adverse Reactions <a href="#ADVERSE_REACTIONS">(6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="WARNINGS_AND_PRECAUTIONS"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_c9a8b96a-2d97-8561-b897-a6f8d0da4973"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 Management of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></span></h2>
<p class="First">Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should use tacrolimus. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physicians responsible for maintenance therapy should have complete information requisite for the follow up of the patient [see <span class="Bold"><a href="#BOXED_WARNING">Boxed Warning</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_c1430800-6a47-a6a5-a2eb-d70663158c0e"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies</span></h2>
<p class="First">Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and other malignancies, particularly of the skin [see <span class="Bold"><a href="#BOXED_WARNING">Boxed Warning</a></span>]. The risk appears to be related to the intensity and duration of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> rather than to the use of any specific agent. </p>
<p>As usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p>
<p><span class="product-label-link" type="condition" conceptid="42872948" conceptname="Post transplant lymphoproliferative disorder">Post transplant lymphoproliferative disorder</span> (PTLD) has been reported in immunosuppressed organ transplant recipients. The majority of PTLD events appear related to Epstein Barr Virus (EBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The risk of PTLD appears greatest in those individuals who are EBV seronegative, a population which includes many young children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_02669390-2e85-f61f-7aac-bc927dd1f4e7"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></h2>
<p class="First">Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing bacterial, viral, fungal, and protozoal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> [see <span class="Bold"><a href="#BOXED_WARNING">Boxed Warning</a></span><span class="Bold"> and Warnings and Precautions (<a href="#_44b3d223-cdaa-0055-c648-e14294ed0028">5.4</a>, <a href="#_efae5194-9a5b-ac74-3462-14bfa59bb652">5.5</a>)</span>]. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may lead to serious, including fatal, outcomes. Because of the danger of oversuppression of the immune system which can increase susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, combination immunosuppressant therapy should be used with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_44b3d223-cdaa-0055-c648-e14294ed0028"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Polyoma Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></h2>
<p class="First">Patients receiving immunosuppressants, including tacrolimus, are at increased risk for <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, including polyoma virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Polyoma virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in transplant patients may have serious, and sometimes fatal, outcomes. These include polyoma virus-associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> (PVAN), mostly due to BK virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and JC virus-associated <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML) which have been observed in patients receiving tacrolimus [see <span class="Bold">Adverse Reactions <a href="#_6ea32ae2-557c-b062-f84e-a2978a187ab5">(6.2)</a></span>].</p>
<p>PVAN is associated with serious outcomes, including deteriorating renal function and kidney graft loss [see <span class="Bold">Adverse Reactions <a href="#_6ea32ae2-557c-b062-f84e-a2978a187ab5">(6.2)</a></span>]. Patient monitoring may help detect patients at risk for PVAN.</p>
<p>Cases of PML have been reported in patients treated with tacrolimus.  PML, which is sometimes fatal, commonly presents with <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, cognitive deficiencies and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms and consultation with a neurologist should be considered as clinically indicated.</p>
<p>Reductions in <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> should be considered for patients who develop evidence of PVAN or PML. Physicians should also consider the risk that reduced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> represents to the functioning allograft.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_efae5194-9a5b-ac74-3462-14bfa59bb652"></a><a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.5 Cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span><span class="Bold"></span>
</h2>
<p class="First">Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> and CMV disease. The risk of CMV disease is highest among transplant recipients seronegative for CMV at time of transplant who receive a graft from a CMV seropositive donor. Therapeutic approaches to limiting CMV disease exist and should be routinely provided. Patient monitoring may help detect patients at risk for CMV disease. Consideration should be given to reducing the amount of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in patients who develop <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> and/or CMV disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_773498b8-5185-3ab8-d970-77c806ec54bd"></a><a name="section-5.6"></a><p></p>
<h2>
<span class="Bold">5.6 New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant</span><span class="Bold"></span>
</h2>
<p class="First">Tacrolimus was shown to cause new onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in clinical trials of kidney and liver transplantation. New onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> after transplantation may be reversible in some patients. Black and Hispanic kidney transplant patients are at an increased risk. Blood glucose concentrations should be monitored closely in patients using tacrolimus [see <span class="Bold">Adverse Reactions <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_646586f3-4314-3d61-f221-3d0e7562ad4f"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></span></h2>
<p class="First">Tacrolimus, like other calcineurin-inhibitors, can cause acute or chronic <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, particularly when used in high doses. Acute <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> is most often related to <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> of the afferent renal arteriole, is characterized by increasing serum creatinine, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and/or a decrease in urine output, and is typically reversible. Chronic calcineurininhibitor <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> is associated with increased serum creatinine, decreased kidney graft life, and characteristic histologic changes observed on renal biopsy; the changes associated with chronic calcineurin-inhibitor <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> are typically progressive. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> should be monitored closely as the dosage of tacrolimus may need to be reduced. In patients with persistent elevations of serum creatinine who are unresponsive to dosage adjustments, consideration should be given to changing to another immunosuppressive therapy.</p>
<p>Based on reported adverse reactions terms related to decreased renal function, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> was reported in approximately 52% of kidney transplantation patients and in 40% and 36% of liver transplantation patients receiving tacrolimus in the U.S. and European randomized trials, respectively, and in 59% of heart transplantation patients in a European randomized trial  [see <span class="Bold">Adverse Reactions <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a>].</span></p>
<p>Due to the potential for additive or synergistic impairment of renal function, care should be taken when administering tacrolimus with drugs that may be associated with renal dysfunction. These include, but are not limited to, aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors (e.g., tenofovir) and protease inhibitors (e.g., ritonavir, indinavir). Similarly, care should be exercised when administering with CYP3A4 inhibitors such as antifungal drugs (e.g., ketoconazole), calcium channel blockers (e.g., diltiazem, verapamil), and macrolide antibiotics (e.g., clarithromycin, erythromycin, troleandomycin) which will result in increased tacrolimus whole blood concentrations due to inhibition of tacrolimus metabolism [see <span class="Bold">Drug Interactions (<a href="#_3447c8d3-0e24-1461-e6b5-a4f7a84bd9d7">7.3,</a><a href="#_ff7f9ee1-7369-84a6-6e82-2f2ed520c272">7.4,</a><a href="#_41c0b559-2679-99f5-4217-e0570466e7a5">7.5</a>, <a href="#_3c8ae943-bac2-4d95-a42b-5cd0e78815b2">7.6</a>)</span>].<span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_6c58d880-0731-32f6-fc2f-48b62ea0f34c"></a><a name="section-5.8"></a><p></p>
<h2><span class="Bold">5.8 <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></span></h2>
<p class="First">Tacrolimus may cause a spectrum of neurotoxicities, particularly when used in high doses. The most severe neurotoxicities include posterior reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> syndrome (PRES), <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Patients treated with tacrolimus have been reported to develop PRES. Symptoms indicating PRES include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, altered mental status, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Diagnosis may be confirmed by radiological procedure. If PRES is suspected or diagnosed, blood pressure control should be maintained and immediate reduction of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> is advised. This syndrome is characterized by reversal of symptoms upon reduction or discontinuation of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span> and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, in the absence of PRES, have also been associated with high plasma concentrations of tacrolimus. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have occurred in adult and pediatric patients receiving tacrolimus [see <span class="Bold">Adverse</span><span class="Bold">Reactions <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a>].</span></p>
<p>Less severe neurotoxicities, include <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and other changes in motor function, mental status, and sensory function [see <span class="Bold">Adverse Reactions </span><span class="Bold"><a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a></span>]. <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have been associated with high whole-blood concentrations of tacrolimus and may respond to dosage adjustment.<span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_387963e5-2598-e73d-af6c-19d0dd2730e8"></a><a name="section-5.9"></a><p></p>
<h2><span class="Bold">5.9 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> has been reported with tacrolimus use. Serum potassium levels should be monitored. Careful consideration should be given prior to use of other agents also associated with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy[see <span class="Bold">Adverse Reactions <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_705070f6-9650-af7d-b658-b66fead6566c"></a><a name="section-5.10"></a><p></p>
<h2><span class="Bold">5.10 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> is a common adverse effect of tacrolimus therapy and may require antihypertensive therapy [see <span class="Bold">Adverse Reactions (6.1)</span>]. The control of blood pressure can be accomplished with any of the common antihypertensive agents, though careful consideration should be given prior to use of antihypertensive agents associated with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) [see <span class="Bold">Warnings and Precautions <a href="#_387963e5-2598-e73d-af6c-19d0dd2730e8">(5.9)</a></span>].</p>
<p>Calcium-channel blocking agents may increase tacrolimus blood concentrations and therefore require dosage reduction of tacrolimus [see <span class="Bold">Drug Interactions <a href="#_41c0b559-2679-99f5-4217-e0570466e7a5">(7.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_21503048-1fac-0eb3-da71-b995151e9c67"></a><a name="section-5.11"></a><p></p>
<h2>
<span class="Bold">5.11 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> with Tacrolimus Injection</span><span class="Bold"></span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have occurred with injectables containing castor oil derivatives, including tacrolimus, in a small percentage of patients (0.6%). The exact cause of these reactions is not known. Tacrolimus injection should be reserved for patients who are unable to take tacrolimus capsules.</p>
<p>Patients receiving tacrolimus injection should be under continuous observation for at least the first 30 minutes following the start of the infusion and at frequent intervals thereafter. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> occur, the infusion should be stopped. An aqueous solution of epinephrine should be available at the bedside as well as a source of oxygen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_e6fb816e-da0b-9c41-17be-6995a0dade06"></a><a name="section-5.12"></a><p></p>
<h2><span class="Bold">5.12 Use with Sirolimus</span></h2>
<p class="First">The safety and efficacy of tacrolimus with sirolimus has not been established in kidney transplant patients. </p>
<p>Use of sirolimus with tacrolimus in studies of de novo liver transplant patients was associated with an excess mortality, graft loss, and <span class="product-label-link" type="condition" conceptid="4223098" conceptname="Hepatic artery thrombosis">hepatic artery thrombosis</span> (HAT) and is not recommended [see <span class="Bold">Indications and Usage </span><span class="Bold"><a href="#_4cfbf8db-143b-728a-cdf8-85eeba93f856">(1.4)</a></span>].</p>
<p>Use of sirolimus (2 mg per day) with tacrolimus in heart transplant patients in a U.S. trial was associated with increased risk of renal function impairment, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing complications, and insulin-dependent post-transplant <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and is not recommended [see <span class="Bold">Clinical Studies (</span><span class="Bold"><a href="#_ffaafd59-ab63-c1bc-003d-3f7ccb173898">14.3</a></span><span class="Bold">)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_dc63967f-8dce-04c0-f4a6-b5609d0483f7"></a><a name="section-5.13"></a><p></p>
<h2><span class="Bold">5.13 Use with CYP3A4 Inhibitors and Inducers</span></h2>
<p class="First">When coadministering tacrolimus with strong CYP3A4-inhibitors (e.g., telaprevir, boceprevir, ritonavir, ketoconazole, itraconazole, voriconazole, clarithromycin) and strong inducers (e.g., rifampin, rifabutin) adjustments in the dosing regimen of tacrolimus and subsequent frequent monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions are recommended  [see <span class="Bold">Drug Interactions </span><span class="Bold"><a href="#DRUG_INTERACTIONS">(7)</a></span>].   </p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_27aa2a64-7011-ee51-8b2a-d5252cbe81a2"></a><a name="section-5.14"></a><p></p>
<h2><span class="Bold">5.14 QT Prolongation</span></h2>
<p class="First">Tacrolimus may prolong the QT/QTc interval and may cause <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>. Avoid tacrolimus in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>. In patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> such as <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, consider obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.  </p>
<p>When coadministering tacrolimus with other substrates and/or inhibitors of CYP3A4 that also have the potential to prolong the QT interval, a reduction in tacrolimus dose, frequent monitoring of tacrolimus whole blood concentrations, and monitoring for QT prolongation is recommended. Use of tacrolimus with amiodarone has been reported to result in increased tacrolimus whole blood concentrations with or without concurrent QT prolongation [see <span class="Bold">Drug Interactions <a href="#DRUG_INTERACTIONS"> (7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_d029624c-cc25-d6ca-5e0d-f793ae29f66a"></a><a name="section-5.15"></a><p></p>
<h2><span class="Bold">5.15 Myocardial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">Hypertrophy</span></span></h2>
<p class="First">Myocardial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> has been reported in infants, children, and adults, particularly those with high tacrolimus trough concentrations, and is generally manifested by echocardiographically demonstrated concentric increases in left ventricular posterior wall and interventricular septum thickness. This condition appears reversible in most cases following dose reduction or discontinuance of therapy. In patients who develop <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> or clinical manifestations of ventricular dysfunction while receiving tacrolimus therapy, echocardiographic evaluation should be considered. If myocardial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> is diagnosed, dosage reduction or discontinuation of tacrolimus should be considered [see <span class="Bold">Adverse Reactions </span><span class="Bold"><a href="#_6ea32ae2-557c-b062-f84e-a2978a187ab5">(6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_fef74a58-2fff-8264-0a04-7917ca25611d"></a><a name="section-5.16"></a><p></p>
<h2><span class="Bold">5.16 Immunizations</span></h2>
<p class="First">The use of live vaccines should be avoided during treatment with tacrolimus; examples include (not limited to) the following: intranasal <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, oral <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span>, BCG, <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">yellow fever</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and TY21a <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> vaccines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_c8082f53-9883-3ed8-8a77-6b64f1d2bd71"></a><a name="section-5.17"></a><p></p>
<h2><span class="Bold">5.17 Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span></span></h2>
<p class="First">Cases of pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> (PRCA) have been reported in patients treated with tacrolimus. A mechanism for tacrolimus-induced PRCA has not been elucidated. All patients reported risk factors for PRCA such as parvovirus B19 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, underlying disease, or concomitant medications associated with PRCA. If PRCA is diagnosed, discontinuation of tacrolimus should be considered [see <span class="Bold">Adverse Reactions </span><span class="Bold"><a href="#_6ea32ae2-557c-b062-f84e-a2978a187ab5">(6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_1f1e13ba-1243-b441-77b4-0b1e91817374"></a><a name="section-5.18"></a><p></p>
<h2><span class="Bold">5.18 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforation</span> has been reported in patients treated with sirolimus; all reported cases were considered to be a complication of transplant surgery or accompanied by <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4150051" conceptname="Diverticulum">diverticulum</span>, or malignant neoplasm. As <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> may be serious or life-threatening, appropriate medical/surgical management should be instituted promptly [see <span class="Bold">Adverse Reactions <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2"> (6.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies [see <span class="Bold"><a href="#BOXED_WARNING">Box Warning</a></span>, <span class="Bold">Warnings and Precautions <a href="#_c1430800-6a47-a6a5-a2eb-d70663158c0e"> (5.2)</a></span>]</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> [see <span class="Bold"><a href="#BOXED_WARNING">Boxed Warning</a>, Warnings and Precautions <a href="#_02669390-2e85-f61f-7aac-bc927dd1f4e7">(5.3)</a></span>]</li>
<li>Polyoma Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> [see <span class="Bold"><a href="#BOXED_WARNING">Boxed Warning</a>, Warnings and Precautions <a href="#_44b3d223-cdaa-0055-c648-e14294ed0028">(5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV Infections</span> [see <span class="Bold"><a href="#BOXED_WARNING">Boxed Warning</a>, Warnings and Precautions <a href="#_efae5194-9a5b-ac74-3462-14bfa59bb652"> (5.5)</a></span>] </li>
<li>New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant [see <span class="Bold">Warnings and Precautions <a href="#_773498b8-5185-3ab8-d970-77c806ec54bd"> (5.6)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> [see <span class="Bold">Warnings and Precautions <a href="#_646586f3-4314-3d61-f221-3d0e7562ad4f"> (5.7)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span> [see <span class="Bold">Warnings and Precautions <a href="#_6c58d880-0731-32f6-fc2f-48b62ea0f34c"> (5.8)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> [see <span class="Bold">Warnings and Precautions <a href="#_387963e5-2598-e73d-af6c-19d0dd2730e8"> (5.9)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> [see <span class="Bold">Warnings and Precautions <a href="#_705070f6-9650-af7d-b658-b66fead6566c"> (5.10</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> with Tacrolimus Injection [see <span class="Bold">Warnings and Precautions <a href="#_21503048-1fac-0eb3-da71-b995151e9c67">(5.11)</a></span>]</li>
<li>Myocardial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">Hypertrophy</span> [see <span class="Bold">Warnings and Precautions <a href="#_d029624c-cc25-d6ca-5e0d-f793ae29f66a"> (5.15)</a></span>]</li>
<li>Pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">Red Cell Aplasia</span> [see <span class="Bold">Warnings and Precautions <a href="#_c8082f53-9883-3ed8-8a77-6b64f1d2bd71"> (5.17)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforation</span> [see <span class="Bold">Warnings and Precautions <a href="#_1f1e13ba-1243-b441-77b4-0b1e91817374"> (5.18)</a></span>]</li>
</ul>
<p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Studies Experience</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In addition, the clinical trials were not designed to establish comparative differences across study arms with regards to the adverse reactions discussed below.</p>
<p>Kidney Transplant</p>
<p>The incidence of adverse reactions was determined in three randomized kidney transplant trials. One of the trials used azathioprine (AZA) and corticosteroids and two of the trials used mycophenolate mofetil (MMF) and corticosteroids concomitantly for maintenance <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>.</p>
<p>Tacrolimus-based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in conjunction with azathioprine and corticosteroids following kidney transplantation was assessed in trial where 205 patients received tacrolimus based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> and 207 patients received cyclosporine based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. The trial population had a mean age of 43 years (mean±sd was 43±13 years on tacrolimus and 44±12 years on cyclosporine arm), the distribution was 61% male, and the composition was White (58%), Black (25%), Hispanic (12%) and Other (5%). The 12 month post-transplant information from this trial is presented below.</p>
<p>The most common adverse reactions ( ≥ 30%) observed in tacrolimus-treated kidney transplant patients are: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, abnormal renal function, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>Adverse reactions that occurred in ≥ 15% of kidney transplant patients treated with tacrolimus in conjunction with azathioprine are presented below:</p>
<p><span class="Bold">Table 4. Kidney Transplantation: Adverse Reactions Occurring in ≥ 15% of Patients Treated with Tacrolimus in Conjunction with Azathioprine (AZA)</span></p>
<p></p>
<table border="0" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless">
<tr class="First">
<td valign="top"> </td>
<td valign="top">
<span class="Bold">Tacrolimus/AZA </span><span class="Bold">(N=205)</span>
</td>
<td valign="top"><span class="Bold">Cyclosporine/AZA (N=207)</span></td>
</tr>
<tr>
<td valign="top">
<span class="Bold">Nervous System</span><br><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> <br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <br><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> <br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> <br><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td valign="top">54%<br>44%<br>32%<br>23%<br>19%</td>
<td valign="top">34%<br>38%<br>30%<br>16%<br>16%</td>
</tr>
<tr>
<td><span class="Bold">Gastrointestinal </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> <br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> <br><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> <br>Vomiting <br><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td valign="top">44%<br>38%<br>35%<br>29%<br>28%</td>
<td valign="top">41%<br>36%<br>43%<br>23%<br>20%</td>
</tr>
<tr>
<td><span class="Bold">Cardiovascular </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <br><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span> </td>
<td>50%<br>19%</td>
<td>52%<br>13%</td>
</tr>
<tr>
<td><span class="Bold">Urogenital </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td>Creatinine Increased <br><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> </td>
<td>45%<br>34%</td>
<td>42%<br>35%</td>
</tr>
<tr>
<td><span class="Bold">Metabolic and Nutritional </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span> <br><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> <br><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipemia</span> <br><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> <br><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus <br><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> <br><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> <br><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </td>
<td valign="top">49%<br>34%<br>31%<br>31%<br>24%<br>22%<br>22%<br>18%</td>
<td valign="top">53%<br>17%<br>38%<br>32%<br>9%<br>25%<br>16%<br>19%</td>
</tr>
<tr>
<td><span class="Bold">Hemic and Lymphatic </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> <br><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> </td>
<td>30%<br>15%</td>
<td>24%<br>17%</td>
</tr>
<tr>
<td><span class="Bold">Miscellaneous </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </td>
<td valign="bottom">45%</td>
<td valign="bottom">49%</td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span> <br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> <br><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> <br><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> <br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> <br><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span> </td>
<td valign="bottom">36% <br>34% <br>33% <br>32% <br>29% <br>24% </td>
<td valign="bottom">48% <br>30% <br>31% <br>30% <br>29% <br>20% </td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">Respiratory System </span></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span> </td>
<td valign="bottom">22% <br>18% </td>
<td valign="bottom">18% <br>15% </td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">Musculoskeletal </span></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td valign="bottom">25% </td>
<td valign="bottom">24% </td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">Skin </span></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr class="Last">
<td valign="bottom"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td valign="bottom">17% <br>15% </td>
<td valign="bottom">12% <br>7% </td>
</tr>
</tbody></table>
<p>Two trials were conducted for tacrolimus-based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in conjunction with MMF and corticosteroids. In the non-US trial (Study 1), the incidence of adverse reactions was based on 1195 kidney transplant patients that received tacrolimus (Group C, n=403), or one of two cyclosporine (CsA) regimens (Group A, n=384 and Group B, n=408) in combination with MMF and corticosteroids; all patients, except those in one of the two cyclosporine groups, also receivedinduction with daclizumab. The trial population had a mean age of 46 years (range 17 to 76), the distribution was 65% male, and the composition was 93% Caucasian. The 12 month post-transplant information from this trial is presented below.</p>
<p>Adverse reactions that occurred in ≥ 10% of kidney transplant patients treated with tacrolimus in conjunction with MMF in Study 1 [Note: This trial was conducted entirely outside of the United States. Such trials often report a lower incidence of adverse reactions in comparison to U.S. trials] are presented below:</p>
<p><span class="Bold">Table 5. Kidney Transplantation: Adverse Reactions Occurring in ≥ 10% of Patients Treated with Tacrolimus in Conjunction with MMF (Study 1)</span></p>
<p></p>
<table border="1" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td colspan="1" rowspan="1" valign="top"> </td>
<td valign="top"><span class="Bold">Tacrolimus</span></td>
<td valign="top"><span class="Bold">Cyclosporine</span></td>
<td valign="top"><span class="Bold">Cyclosporine</span></td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"><span class="Bold">(Group C)</span></td>
<td valign="top"><span class="Bold">(Group A)</span></td>
<td valign="top"><span class="Bold">(Group B)</span></td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"><span class="Bold">(N=403)</span></td>
<td valign="top"><span class="Bold">(N=384)</span></td>
<td valign="top"><span class="Bold">(N=408)</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td valign="top">25%</td>
<td valign="top">16%</td>
<td valign="top">13%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> </td>
<td>24%</td>
<td>28%</td>
<td>24%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </td>
<td valign="top">17%</td>
<td valign="top">19%</td>
<td valign="top">17%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </td>
<td>13%</td>
<td>14%</td>
<td>12%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td valign="top">13%</td>
<td valign="top">10%</td>
<td valign="top">10%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema Peripheral</span> </td>
<td valign="top">11%</td>
<td valign="top">12%</td>
<td valign="top">13%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> </td>
<td valign="top">10%</td>
<td valign="top">15%</td>
<td valign="top">13%</td>
</tr>
<tr class="Last"><td align="left" colspan="4">Key: Group A = CsA/MMF/CS, B = CsA/MMF/CS/Daclizumab, C=Tac/MMF/CS/Daclizumab CsA = Cyclosporine, CS = Corticosteroids, Tac = Tacrolimus, MMF = mycophenolate mofetil </td></tr>
</tbody></table>
<p></p>
<p>In the U.S. trial (Study 2) with tacrolimus-based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in conjunction with MMF and corticosteroids, 424 kidney transplant patients received tacrolimus (n=212) or cyclosporine (n=212) in combination with MMF 1 gram twice daily, basiliximab induction, and corticosteroids. The trial population had a mean age of 48 years (range 17 to 77), the distribution was 63% male, and the composition was White (74%), Black (20%), Asian (3%) and other (3%). The 12 month post-transplant information from this trial is presented below.</p>
<p>Adverse reactions that occurred in ≥15% of kidney transplant patients treated with tacrolimus in conjunction with MMF in Study 2 are presented below:</p>
<p><span class="Bold">Table 6. Kidney Transplantation: Adverse Reactions Occurring in ≥ 15% of Patients Treated with Tacrolimus in Conjunction with MMF (Study 2)</span></p>
<p></p>
<table border="0" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless">
<tr class="First">
<td valign="top"> </td>
<td valign="top"><span class="Bold">Tacrolimus/MMF </span></td>
<td valign="top"><span class="Bold">Cyclosporine/MMF </span></td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"><span class="Bold">(N=212) </span></td>
<td valign="top"><span class="Bold">(N=212) </span></td>
</tr>
<tr>
<td valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td>44% </td>
<td>26% </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td>39% </td>
<td>47% </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td> 36% </td>
<td>41% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td valign="top">26% </td>
<td valign="top">25% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td valign="top">18% </td>
<td valign="top">15% </td>
</tr>
<tr>
<td><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>, and Procedural Complications </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="top">Post-<span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">Procedural Pain</span> </td>
<td valign="top">29% </td>
<td valign="top">27% </td>
</tr>
<tr>
<td>Incision Site Complication </td>
<td>28% </td>
<td>23% </td>
</tr>
<tr>
<td valign="top">Graft Dysfunction </td>
<td valign="top">24% </td>
<td valign="top">18% </td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">Metabolism and Nutrition Disorders </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> </td>
<td>28% </td>
<td>22% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span> </td>
<td valign="top">28% </td>
<td valign="top">21% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> </td>
<td valign="top">26% </td>
<td valign="top">19% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </td>
<td valign="top">21% </td>
<td valign="top">15% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> </td>
<td valign="top">18% </td>
<td valign="top">25% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> </td>
<td valign="top">16% </td>
<td valign="top">18% </td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </td>
<td valign="top">34% </td>
<td valign="top">20% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td valign="top">24% </td>
<td valign="top">25% </td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">Blood and Lymphatic System Disorders </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </td>
<td valign="top">30% </td>
<td valign="top">28% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td valign="top"> 16% </td>
<td valign="top">12% </td>
</tr>
<tr>
<td valign="bottom"><span class="Bold">Miscellaneous </span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema Peripheral</span> </td>
<td>35% </td>
<td>46% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </td>
<td valign="top">32% </td>
<td valign="top">35% </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td valign="top">30% </td>
<td valign="top">21% </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> </td>
<td>26% </td>
<td>22% </td>
</tr>
<tr class="Last">
<td valign="top">Blood Creatinine Increased </td>
<td valign="top">23% </td>
<td valign="top">23% </td>
</tr>
</tbody></table>
<p>Less frequently observed adverse reactions in both liver transplantation and kidney transplantation patients are described under the subsection Less Frequently Reported Adverse Reactions.</p>
<p>Liver Transplantation</p>
<p>There were two randomized comparative liver transplant trials. In the U.S. trial, 263 adult and pediatric patients received tacrolimus and steroids and 266 patients received cyclosporine-based immunosuppressive regimen (CsA/AZA). The trial population had a mean age of 44 years (range 0.4 to70), the distribution was 52% male, and the composition was White (78%), Black (5%), Asian (2%), Hispanic (13%) and Other (2%). In the European trial, 270 patients received tacrolimus and steroids and 275 patients received CsA/AZA. The trial population had a mean age of 46 years (range 15 to 68), the distribution was 59% male, and the composition was White (95.4%), Black (1%), Asian (2%) and Other (2%).</p>
<p>The proportion of patients reporting more than one adverse event was &gt; 99% in both the tacrolimus group and the CsA/AZA group. Precautions must be taken when comparing the incidence of adverse reactions in the U.S. trial to that in the European trial. The 12-month post-transplant information from the U.S. trial and from the European trial is presented below. The two trials also included different patient populations and patients were treated with immunosuppressive regimens of differing intensities. Adverse reactions reported in ≥15% in tacrolimus patients (combined trial results) are presented below for the two controlled trials in liver transplantation. </p>
<p>The most common adverse reactions (≥ 40%) observed in tacrolimus-treated liver transplant patients are: <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, abnormal renal function, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. These all occur with oral and IV administration of tacrolimus and some may respond to a reduction in dosing (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>). <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was sometimes associated with other gastrointestinal complaints such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Bold">Table 7. Liver Transplantation: Adverse Reactions Occurring in ≥ 15% of Patients Treated with Tacrolimus </span></p>
<table frame="box"><tbody class="Headless">
<tr class="First">
<td></td>
<td><span class="Bold">U.S. TRIAL</span></td>
<td></td>
<td><span class="Bold">EUROPEAN TRIAL</span></td>
<td></td>
</tr>
<tr>
<td> </td>
<td>Tacrolimus</td>
<td>Cyclosporine/</td>
<td>Tacrolimus</td>
<td>Cyclosporine/</td>
</tr>
<tr>
<td> </td>
<td>(N=250)</td>
<td>AZA</td>
<td>(N=264)</td>
<td>AZA</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td>(N=250)</td>
<td> </td>
<td>(N=265)</td>
</tr>
<tr>
<td><span class="Bold">Nervous System </span></td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td>64%</td>
<td>60%</td>
<td>37%</td>
<td>26%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td>64%</td>
<td>68%</td>
<td>32%</td>
<td>23%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </td>
<td>56%</td>
<td>46%</td>
<td>48%</td>
<td>32%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> </td>
<td>40%</td>
<td>30%</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>Gastrointestinal </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td>72%</td>
<td>47%</td>
<td>37%</td>
<td>27%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td>46%</td>
<td>37%</td>
<td>32%</td>
<td>27%</td>
</tr>
<tr>
<td>LFT Abnormal </td>
<td>36%</td>
<td>30%</td>
<td>6%</td>
<td>5%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </td>
<td>34%</td>
<td>24%</td>
<td>7%</td>
<td>5%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td>27%</td>
<td>15%</td>
<td>14%</td>
<td>11%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td>24%</td>
<td>27%</td>
<td>23%</td>
<td>21%</td>
</tr>
<tr>
<td>Cardiovascular </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </td>
<td>47%</td>
<td>56%</td>
<td>38%</td>
<td>43%</td>
</tr>
<tr>
<td>Urogenital </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Kidney Function Abnormal</span> </td>
<td>40%</td>
<td>27%</td>
<td>36%</td>
<td>23%</td>
</tr>
<tr>
<td>Creatinine Increased </td>
<td>39%</td>
<td>25%</td>
<td>24%</td>
<td>19%</td>
</tr>
<tr>
<td>BUN Increased </td>
<td>30%</td>
<td>22%</td>
<td>12%</td>
<td>9%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span> </td>
<td>18%</td>
<td>15%</td>
<td>19%</td>
<td>12%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> </td>
<td>16%</td>
<td>18%</td>
<td>21%</td>
<td>19%</td>
</tr>
<tr>
<td>Metabolic and Nutritional </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></td>
<td>48%</td>
<td>45%</td>
<td>16%</td>
<td>9%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </td>
<td>47%</td>
<td>38%</td>
<td>33%</td>
<td>22%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> </td>
<td>45%</td>
<td>26%</td>
<td>13%</td>
<td>9%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td>29%</td>
<td>34%</td>
<td>13%</td>
<td>16%</td>
</tr>
<tr>
<td>Hemic and Lymphatic </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </td>
<td>47%</td>
<td>38%</td>
<td>5%</td>
<td>1%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span></td>
<td>32%</td>
<td>26%</td>
<td>8%</td>
<td>8%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td>24%</td>
<td>20%</td>
<td>14%</td>
<td>19%</td>
</tr>
<tr>
<td>Miscellaneous </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td>63%</td>
<td>57%</td>
<td>24%</td>
<td>22%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> </td>
<td>59%</td>
<td>54%</td>
<td>29%</td>
<td>22%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </td>
<td>52%</td>
<td>48%</td>
<td>11%</td>
<td>7%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </td>
<td>48%</td>
<td>56%</td>
<td>19%</td>
<td>22%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span> </td>
<td>30%</td>
<td>29%</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span> </td>
<td>27%</td>
<td>22%</td>
<td>7%</td>
<td>8%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></td>
<td>26%</td>
<td>26%</td>
<td>12%</td>
<td>14%</td>
</tr>
<tr>
<td>Respiratory System </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural Effusion</span> </td>
<td>30%</td>
<td>32%</td>
<td>36%</td>
<td>35%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> </td>
<td>29%</td>
<td>23%</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="261880" conceptname="Atelectasis">Atelectasis</span></td>
<td>28%</td>
<td>30%</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Skin and Appendages </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </td>
<td>36%</td>
<td>20%</td>
<td>15%</td>
<td>7%</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td>24%</td>
<td>19%</td>
<td>10%</td>
<td>4%</td>
</tr>
</tbody></table>
<p></p>
<p></p>
<p>Less frequently observed adverse reactions in both liver transplantation and kidney transplantation patients are described under the subsection Less Frequently Reported Adverse Reactions.</p>
<p>Heart Transplantation</p>
<p>The incidence of adverse reactions was determined based on two trials in primary orthotopic heart transplantation. In a trial conducted in Europe, 314 patients received a regimen of antibody induction, corticosteroids and azathioprine (AZA) in combination with tacrolimus (n=157) or cyclosporine (n=157) for 18 months. The trial population had a mean age of 51 years (range 18 to 65), the distribution was 82% male, and the composition was White (96%), Black (3%) and other(1%).</p>
<p>The most common adverse reactions (≥ 15%) observed in tacrolimus-treated heart transplant patients are: abnormal renal function, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>. </p>
<p>Adverse reactions in heart transplant patients in the European trial are presented below:</p>
<p><span class="Bold">Table 8. Heart Transplantation: Adverse Reactions Occurring in ≥ 15% of Patients Treated with Tacrolimus in Conjunction with Azathioprine (AZA)</span></p>
<table frame="box"><tbody class="Headless">
<tr class="First">
<td> </td>
<td>Tacrolimus/AZA (n=157)</td>
<td>Cyclosporine/AZA(n=157)</td>
</tr>
<tr>
<td>Cardiovascular System </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </td>
<td>62% </td>
<td>69%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial Effusion</span> </td>
<td>15% </td>
<td>14%</td>
</tr>
<tr>
<td>Body as a Whole </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV Infection</span> </td>
<td>32% </td>
<td>30%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </td>
<td>24% </td>
<td>21%</td>
</tr>
<tr>
<td>Metabolic and Nutritional Disorders </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus </td>
<td>26% </td>
<td>16%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </td>
<td>23% </td>
<td>17%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipemia</span> </td>
<td>18% </td>
<td>27%</td>
</tr>
<tr>
<td>Hemic and Lymphatic System </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </td>
<td>50% </td>
<td>36%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td> 48% </td>
<td>39%</td>
</tr>
<tr>
<td>Urogenital System </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Kidney Function Abnormal</span> </td>
<td>56% </td>
<td>57%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> </td>
<td>16% </td>
<td>12%</td>
</tr>
<tr>
<td>Respiratory System </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span> </td>
<td>17% </td>
<td>18%</td>
</tr>
<tr>
<td>Nervous System </td>
<td> </td>
<td> </td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </td>
<td>15% </td>
<td>6%</td>
</tr>
</tbody></table>
<p>In the European trial, the cyclosporine trough concentrations were above the pre-defined target range (i.e., 100 to 200 ng/mL) at Day 122 and beyond in 32 to 68% of the patients in the cyclosporine treatment arm, whereas the tacrolimus trough concentrations were within the pre-defined target range (i.e., 5 to 15 ng/mL) in 74 to 86% of the patients in the tacrolimus treatment arm.</p>
<p>In a U.S. trial, the incidence of adverse reactions was based on 331 heart transplant patients that received corticosteroids and tacrolimus in combination with sirolimus (n=109), tacrolimus in combination with MMF (n=107) or cyclosporine modified in combination with MMF (n=115) for 1 year. The trial population had a mean age of 53 years (range 18 to 75), the distribution was 78% male, and the composition was White (83%), Black (13%) and other (4%).</p>
<p>Only selected targeted treatment-emergent adverse reactions were collected in the U.S. heart transplantation trial. Those reactions that were reported at a rate of 15% or greater in patients treated with tacrolimus and MMF include the following: any target adverse reactions (99%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (89%), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> requiring antihyperglycemic therapy (70%), <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> (65%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (hemoglobin &lt;10.0 g/dL) (65%), fasting blood glucose &gt;140 mg/dL (on two separate occasions) (61%), <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (57%), <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (34%), WBCs &lt;3000 cells/mcL (34%), serious <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> (30%), magnesium &lt;1.2 mEq/L (24%), platelet count &lt;75,000 cells/mcL (19%), and other <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (15%).</p>
<p>Other targeted treatment-emergent adverse reactions in tacrolimus-treated patients occurred at a rate of less than 15%, and include the following: <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> features, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>,<span class="Italics"> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>/syndrome.</p>
<p><span class="Bold">New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant</span></p>
<p>Kidney Transplant</p>
<p>New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant (NODAT) is defined as a composite of fasting plasma glucose ≥126 mg/dL, HbA<span class="Sub">1C</span> ≥ 6%, insulin use ≥ 30 days or oral hypoglycemic use. In a trial in kidney transplant patients (Study 2), NODAT was observed in 75% in the tacrolimus-treated and 61% in the Neoral-treated patients without pre-transplant history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (Table 9) [see <span class="Bold">Clinical Studies <a href="#_df213488-e1ee-4264-95f9-0422aedfd287">(14.1)</a></span>].</p>
<p><span class="Bold">Table 9. Incidence of New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant at 1 year in Kidney Transplant Recipients in a Phase 3 Trial (Study 2)</span></p>
<p></p>
<table border="1" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td rowspan="2" valign="top"><span class="Bold">Parameter</span></td>
<td colspan="2" valign="top"><span class="Bold">       Treatment Group </span></td>
</tr>
<tr>
<td>
<span class="Bold">Tacrolimus/MMF</span><span class="Bold">(n = 212)</span>
</td>
<td>
<span class="Bold">Neoral/MMF</span><span class="Bold">(n = 212)</span>
</td>
</tr>
<tr>
<td align="left">NODAT </td>
<td align="center">112/150 (75%) </td>
<td>93/152 (61%) </td>
</tr>
<tr>
<td align="left">Fasting Plasma Glucose ≥ 126 mg/dL </td>
<td>96/150 (64%) </td>
<td>80/152 (53%) </td>
</tr>
<tr>
<td align="left">HbA<span class="Sub">1C </span>≥ 6% </td>
<td>59/150 (39%) </td>
<td>28/152 (18%) </td>
</tr>
<tr>
<td align="left">Insulin Use ≥ 30 days </td>
<td>9/150 (6%) </td>
<td>4/152 (3%) </td>
</tr>
<tr class="Last">
<td align="left" valign="bottom">Oral Hypoglycemic Use </td>
<td valign="bottom">15/150 (10%) </td>
<td valign="bottom">5/152 (3%) </td>
</tr>
</tbody></table>
<p>In early trials of tacrolimus, Post-Transplant <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus (PTDM) was evaluated with a more limited criteria of “use of insulin for 30 or more consecutive days with &lt; 5 day gap? in patients without a prior history of insulin-dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or non-insulin dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Data are presented in Tables 10 to 13. PTDM was reported in 20% of Tacrolimus/Azathioprine (AZA)-treated kidney transplant patients without pre-transplant history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in a Phase 3 trial (Table 10). The median time to onset of PTDM was 68 days. Insulin <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> was reversible in 15% of these PTDM patients at one year and in 50% at 2 years post-transplant. Black and Hispanic kidney transplant patients were at an increased risk of development of PTDM (Table 11).</p>
<p></p>
<p><span class="Bold">Table 10. Incidence of Post-Transplant <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and Insulin Use at 2 Years in Kidney Transplant Recipients in a Phase 3 Trial using Azathioprine (AZA)</span></p>
<p></p>
<table border="1" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td align="left" valign="top">
<span class="Bold">Status of PTDM</span><span class="Sup">a</span>
</td>
<td valign="top"><span class="Bold">Tacrolimus/AZA</span></td>
<td valign="top"><span class="Bold">CsA/AZA</span></td>
</tr>
<tr>
<td align="left" valign="top">Patients without pre-transplant history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus</td>
<td valign="top">151</td>
<td valign="top">151</td>
</tr>
<tr>
<td align="left">New onset PTDM<span class="Sup">a</span>, 1<span class="Sup">st</span> Year </td>
<td valign="top">30/151 (20%)</td>
<td valign="top">6/151 (4%)</td>
</tr>
<tr>
<td align="left" valign="top">Still insulin-dependent at one year in those without prior history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></td>
<td valign="top">25/151 (17%)</td>
<td valign="top">5/151 (3%)</td>
</tr>
<tr>
<td align="left" valign="top">New onset PTDM<span class="Sup">a </span>post 1 year </td>
<td valign="top">1</td>
<td valign="top">0</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Patients with PTDM<span class="Sup">a </span> at 2 years </td>
<td valign="top">16/151 (11%)</td>
<td valign="top">5/151 (3%)</td>
</tr>
</tbody></table>
<p><span class="Sup"></span>a) Use of insulin for 30 or more consecutive days, with &lt; 5 day gap, without a prior history of insulin-dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or non-insulin dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.<span class="Bold"> </span><span class="Bold"></span></p>
<p></p>
<p><span class="Bold">Table 11. Development of Post-Transplant <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus by Race or Ethnicity and by Treatment Group During First Year Post Kidney Transplantation in a Phase 3 Trial </span></p>
<table border="1" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td align="left" rowspan="2"><span class="Bold">Patient Race </span></td>
<td colspan="2"><span class="Bold">Patients Who Developed PTDM<span class="Sup">a</span></span></td>
</tr>
<tr>
<td><span class="Bold">Tacrolimus</span></td>
<td><span class="Bold">Cyclosporine</span></td>
</tr>
<tr>
<td align="left">Black </td>
<td>15/41 (37%)</td>
<td>3 (8%)</td>
</tr>
<tr>
<td align="left">Hispanic </td>
<td>5/17 (29%)</td>
<td>1 (6%)</td>
</tr>
<tr>
<td align="left">Caucasian </td>
<td>10/82 (12%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td align="left">Other </td>
<td>0/11 (0%)</td>
<td>1 (10%)</td>
</tr>
<tr class="Last">
<td align="left">Total </td>
<td>30/151 (20%)</td>
<td>6 (4%)</td>
</tr>
</tbody></table>
<p><span class="Bold"></span></p>
<p><span class="Sup"></span>a) Use of insulin for 30 or more consecutive days, with &lt; 5 day gap, without a prior history of insulin-dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or non-insulin dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
<p>Liver Transplant</p>
<p>Insulin-dependent PTDM was reported in 18% and 11% of tacrolimus-treated liver transplant patients and was reversible in 45% and 31% of these patients at 1 year post-transplant, in the U.S. and European randomized trials, respectively, (Table 12). <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> was associated with the use of tacrolimus in 47% and 33% of liver transplant recipients in the U.S. and European randomized trials, respectively, and may require treatment [see <span class="Bold">Adverse Reactions <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1)</a></span>].<span class="Bold"> </span><span class="Bold"></span></p>
<p></p>
<p><span class="Bold">Table 12. Incidence of Post-Transplant <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and Insulin Use at 1 Year in Liver Transplant Recipients</span></p>
<p></p>
<table border="1" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td align="left" rowspan="2" valign="top">
<span class="Bold">Status of PTDM</span><span class="Sup">a </span>
</td>
<td colspan="2"><span class="Bold">US Trial </span></td>
<td colspan="2"><span class="Bold">European Trial </span></td>
</tr>
<tr>
<td><span class="Bold">Tacrolimus</span></td>
<td><span class="Bold">Cyclosporine</span></td>
<td><span class="Bold">Tacrolimus</span></td>
<td><span class="Bold">Cyclosporine</span></td>
</tr>
<tr>
<td align="left" valign="top">Patients at risk<span class="Sup">b</span>
</td>
<td valign="top">239</td>
<td valign="top">236</td>
<td valign="top">239</td>
<td valign="top">249</td>
</tr>
<tr>
<td align="left">New Onset PTDM<span class="Sup">a</span>
</td>
<td valign="top">42 (18%)</td>
<td valign="top">30 (13%)</td>
<td valign="top">26 (11%)</td>
<td valign="top">12 (5%)</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Patients still on insulin at 1 year</td>
<td valign="top">23 (10%)</td>
<td valign="top">19 (8%)</td>
<td valign="top">18 (8%)</td>
<td valign="top">6 (2%)</td>
</tr>
</tbody></table>
<p><span class="Sup"></span>a) Use of insulin for 30 or more consecutive days, with &lt; 5 day gap, without a prior history of insulin-dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or non-insulin dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.<span class="Sup"></span></p>
<p>b) Patients without pre-transplant history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
<p>Heart Transplant</p>
<p>Insulin-dependent PTDM was reported in 13% and 22% of tacrolimus-treated heart transplant patients receiving mycophenolate mofetil (MMF) or azathioprine (AZA) and was reversible in 30% and 17% of these patients at one year post-transplant, in the U.S. and European randomized trials, respectively (Table 13). <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> defined as two fasting plasma glucose levels ≥126 mg/dL was reported with the use of tacrolimus plus MMF or AZA in 32% and 35% of heart transplant recipients in the U.S. and European randomized trials, respectively, and may require treatment [see <span class="Bold">Adverse Reactions (</span><span class="Bold"><a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">6.1</a></span><span class="Bold">)</span>].</p>
<p><span class="Bold">Table 13. Incidence of Post-Transplant <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and Insulin Use at 1 Year in Heart Transplant Recipients</span></p>
<table frame="box" width="85%"><tbody class="Headless">
<tr class="First">
<td>Status of PTDM<span class="Sup">a </span>
</td>
<td>US Trial </td>
<td>European Trial </td>
</tr>
<tr>
<td> </td>
<td>Tacrolimus /MMF </td>
<td>Cyclosporine/MMF </td>
<td>Tacrolimus/ AZA </td>
<td>Cyclosporine/AZA </td>
</tr>
<tr>
<td>Patients at risk<span class="Sup">b</span>
</td>
<td>75</td>
<td> 83 </td>
<td>132 </td>
<td>138 </td>
</tr>
<tr>
<td>New Onset PTDM<span class="Sup">a</span>
</td>
<td>10 (13%) </td>
<td>6 (7%) </td>
<td>29 (22%) </td>
<td>5 (4%) </td>
</tr>
<tr class="Last">
<td>Patients still on insulin at1 year<span class="Sup">c</span>
</td>
<td>7 (9%) </td>
<td>1 (1%) </td>
<td>24 (18%) </td>
<td>4 (3%) </td>
</tr>
</tbody></table>
<p><span class="Sup">a)</span> Use of insulin for 30 or more consecutive days without a prior history of insulin-dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or non-insulin dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.<span class="Sup"></span></p>
<p><span class="Sup">b)</span> Patients without pre-transplant history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.<span class="Sup"></span></p>
<p><span class="Sup">c)</span> 7 to 12 months for the U.S. trial.</p>
<p></p>
<p>Less Frequently Reported Adverse Reactions (&gt;3% and &lt;15%)</p>
<p>The following adverse reactions were reported in either liver, kidney, and/or heart transplant recipients who were treated with tacrolimus in clinical trials. </p>
<p>Nervous System [see <span class="Bold">Warnings and Precautions (</span><span class="Bold"><a href="#_6c58d880-0731-32f6-fc2f-48b62ea0f34c">5.8</a></span><span class="Bold">)</span>] </p>
<p><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4304866" conceptname="Elevated mood">elevated mood</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">haemorrhagic stroke</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4194210" conceptname="Monoparesis">monoparesis</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4164436" conceptname="Peripheral nerve entrapment syndrome">nerve compression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">paralysis flaccid</span>, psychomotor skills impaired, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4339222" conceptname="Dysgraphia">writing impaired</span> </p>
<p>Special Senses</p>
<p><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, tinnitus </p>
<p>Gastrointestinal</p>
<p><span class="product-label-link" type="condition" conceptid="195856" conceptname="Cholangitis">Cholangitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">gastroesophagitis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, GGT increase, GI disorder, <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">GI perforation</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> granulomatous, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, <span class="product-label-link" type="condition" conceptid="4247542" conceptname="Peptic ulcer of esophagus">oesophagitis ulcerative</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4008556" conceptname="Pseudocyst of pancreas">pancreatic pseudocyst</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, stomatitis </p>
<p>Cardiovascular</p>
<p><span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">Abnormal ECG</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">cardiac fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4259490" conceptname="Cardiorespiratory failure">cardiopulmonary failure</span>, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4059699" conceptname="Echocardiogram abnormal">echocardiogram abnormal</span>, electrocardiogram <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> abnormal, electrocardiogram ST segment abnormal, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">heart rate decreased</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disorder</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, vasodilatation  </p>
<p>Urogenital</p>
<p><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute kidney failure</span> [see <span class="Bold">Warnings and Precautions (5.7)</span>], <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, BK <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, <span class="product-label-link" type="condition" conceptid="4090870" conceptname="Spasm of bladder">bladder spasm</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">kidney tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">pyuria</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>  </p>
<p>Metabolic/Nutritional</p>
<p><span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span>, alkaline phosphatase increased, <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>, ALT (SGPT) increased, AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) increased, <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> decreased, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">GGT increased</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4304198" conceptname="Impaired tissue repair">healing abnormal</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, lactic dehydrogenase increase, weight gain </p>
<p>Endocrine</p>
<p>Cushing’s syndrome </p>
<p>Hemic/Lymphatic</p>
<p><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulation disorder</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, haematocrit increased, haemoglobin abnormal, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">hypochromic anemia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> decreased, serum iron decreased </p>
<p>Miscellaneous</p>
<p><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="4310235" conceptname="Reduced mobility">mobility decreased</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, temperature intolerance, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>  </p>
<p>Musculoskeletal</p>
<p><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">generalized spasm</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorder</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>  </p>
<p>RespiratoryAsthma, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span>, lung function decreased, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, voice alteration </p>
<p>Skin</p>
<p><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, neoplasm skin benign, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span><span class="Bold"></span></p>
<p><span class="Bold"></span><span class="Bold"></span><span class="Bold"></span><span class="Bold"></span><span class="Bold"></span><span class="Bold"></span><span class="Bold"></span><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_6ea32ae2-557c-b062-f84e-a2978a187ab5"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">6.2 Postmarketing Adverse Reactions</span></h2>
<p class="First">The following adverse reactions have been reported from worldwide marketing experience with tacrolimus. Because these reactions are reported voluntarily from a population of uncertain size it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of the reporting, or (3)  strength of causal connection to the drug.</p>
<p>Other reactions include:</p>
<p>Cardiovascular</p>
<p><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, electrocardiogram T wave abnormal, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischaemia</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">venous thrombosis deep limb</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, myocardial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> [see <span class="Bold">Warnings and Precautions <a href="#_d029624c-cc25-d6ca-5e0d-f793ae29f66a"> (5.15)</a></span>].</p>
<p>Gastrointestinal</p>
<p><span class="product-label-link" type="condition" conceptid="4182588" conceptname="Stenosis of bile duct">Bile duct stenosis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastrooesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatic cytolysis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, hepatotoxicity, <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">impaired gastric emptying</span>, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">liver fatty</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="4185268" conceptname="Acute hemorrhagic pancreatitis">pancreatitis haemorrhagic</span>, <span class="product-label-link" type="condition" conceptid="4303234" conceptname="Acute necrotizing pancreatitis">pancreatitis necrotizing</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span>, <span class="product-label-link" type="condition" conceptid="4277276" conceptname="Veno-occlusive disease of the liver">venoocclusive liver disease</span></p>
<p>Hemic/Lymphatic</p>
<p><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombocytopenic purpura, thrombotic</span> thrombocytopenic purpura, pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> [see <span class="Bold">Warnings and Precautions <a href="#_c8082f53-9883-3ed8-8a77-6b64f1d2bd71"> (5.17)</a></span>]</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML), sometimes fatal; -polyoma virus-associated <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, (PVAN) including graft loss [see <span class="Bold">Warnings and Precautions <a href="#_44b3d223-cdaa-0055-c648-e14294ed0028">(5.4)</a></span>] </p>
<p>Metabolic/Nutritional</p>
<p><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span>, increased amylase including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, weight decreased </p>
<p>Miscellaneous</p>
<p><span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">Feeling hot</span> and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, multi-organ failure, primary graft dysfunction </p>
<p>Nervous System</p>
<p><span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">Carpal tunnel syndrome</span>, <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span>, <span class="product-label-link" type="condition" conceptid="4065756" conceptname="Hemiparesis">hemiparesis</span>, <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">leukoencephalopathy</span>, <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">mental disorder</span>, <span class="product-label-link" type="condition" conceptid="4339188" conceptname="Mutism">mutism</span>, posterior reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> syndrome (PRES) [see <span class="Bold">Warnings and Precautions <a href="#_6c58d880-0731-32f6-fc2f-48b62ea0f34c">(5.8)</a></span>], <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> (PML) [see <span class="Bold">Warnings and Precautions <a href="#_44b3d223-cdaa-0055-c648-e14294ed0028"> (5.4)</a></span>], <span class="product-label-link" type="condition" conceptid="374914" conceptname="Tetraplegia">quadriplegia</span>, speech disorder, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>  </p>
<p>Respiratory</p>
<p><span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, lung infiltration, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, respiratory failure </p>
<p>Skin</p>
<p><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, toxic epidermal necrolysis </p>
<p>Special Senses</p>
<p><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Blindness</span>, <span class="product-label-link" type="condition" conceptid="253482" conceptname="Cortical blindness">blindness cortical</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> including <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, photophobia </p>
<p>Urogenital</p>
<p><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">cystitis haemorrhagic</span>, hemolytic-<span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremic syndrome</span>, micturition disorder</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DRUG_INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Since tacrolimus is metabolized mainly by CYP3A enzymes, drugs or substances known to inhibit these enzymes may increase tacrolimus whole blood concentrations. Drugs known to induce CYP3A enzymes may decrease tacrolimus whole blood concentrations [see <span class="Bold">Warnings and Precautions <a href="#_dc63967f-8dce-04c0-f4a6-b5609d0483f7">(5.13)</a> and Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>].Dose adjustments may be needed along with frequent monitoring of tacrolimus whole blood trough concentrations when tacrolimus is administered with CYP3A inhibitors or inducers. In addition, patients should be monitored for adverse reactions including changes in renal function and QT prolongation [see <span class="Bold">Warnings and Precautions <a href="#_646586f3-4314-3d61-f221-3d0e7562ad4f">(5.7)</a> and <a href="#_27aa2a64-7011-ee51-8b2a-d5252cbe81a2">(5.14)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_b992fb27-d2dc-9813-f898-40cb4c49a412"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 Mycophenolic Acid Products</span></h2>
<p class="First">With a given dose of mycophenolic acid (MPA) products, exposure to MPA is higher with tacrolimus co-administration than with cyclosporine co-administration because cyclosporine interrupts the enterohepatic recirculation of MPA while tacrolimus does not. Clinicians should be aware that there is also a potential for increased MPA exposure after crossover from cyclosporine to tacrolimus in patients concomitantly receiving MPA-containing products.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ae530d6d-766e-6741-d24b-eb43b2d6d14e"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.2 Grapefruit Juice</span></h2>
<p class="First">Grapefruit juice inhibits CYP3A-enzymes resulting in increased tacrolimus whole blood trough concentrations, and patients should avoid eating grapefruit or drinking grapefruit juice with tacrolimus [see <span class="Bold">Dosage and Administration <a href="#_f4e10115-ade6-2ded-a674-e5294ba195be">(2.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_3447c8d3-0e24-1461-e6b5-a4f7a84bd9d7"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">7.3 Protease Inhibitors</span></h2>
<p class="First">Most protease inhibitors inhibit CYP3A enzymes and may increase tacrolimus whole blood concentrations. It is recommended to avoid concomitant use of tacrolimus with nelfinavir unless the benefits outweigh the risks [see <span class="Bold">Clinical Pharmacology </span><span class="Bold"><a href="#PHARMACOKINETICS">(12.3)</a></span>]. Whole blood concentrations of tacrolimus are markedly increased when co-administered with telaprevir or with boceprevir [see <span class="Bold">Clinical Pharmacology </span><span class="Bold"><a href="#PHARMACOKINETICS">(12.3)</a></span>]. Monitoring of tacrolimus whole blood concentrations and tacrolimus-associated adverse reactions, and appropriate adjustments in the dosing regimen of tacrolimus are recommended when tacrolimus and protease inhibitors (e.g., ritonavir, telaprevir, boceprevir) are used concomitantly. .</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ff7f9ee1-7369-84a6-6e82-2f2ed520c272"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">7.4 Antifungal Agents</span></h2>
<p class="First">Frequent monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when concomitant use of the following antifungal drugs with tacrolimus is initiated or discontinued [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>].</p>
<p>Azoles: Voriconazole, posaconazole, itraconazole, ketoconazole, fluconazole and clotrimazole inhibit CYP3A metabolism of tacrolimus and increase tacrolimus whole blood concentrations. When initiating therapy with voriconazole or posaconazole in patients already receiving tacrolimus, it is recommended that the tacrolimus dose be initially reduced to one-third of the original dose and the subsequent tacrolimus doses be adjusted based on the tacrolimus whole blood concentrations.</p>
<p>Caspofungin is an inducer of CYP3A and decreases whole blood concentrations of tacrolimus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_41c0b559-2679-99f5-4217-e0570466e7a5"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">7.5 Calcium Channel Blockers</span></h2>
<p class="First">Verapamil, diltiazem, nifedipine, and nicardipine inhibit CYP3A metabolism of tacrolimus and may increase tacrolimus whole blood concentrations. Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when these calcium channel blocking drugs and tacrolimus are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_3c8ae943-bac2-4d95-a42b-5cd0e78815b2"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">7.6 Antibacterials</span></h2>
<p class="First">Erythromycin, clarithromycin, troleandomycin and chloramphenicol inhibit CYP3A metabolism of tacrolimus and may increase tacrolimus whole blood concentrations. Monitoring of blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when these drugs and tacrolimus are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_36fabc49-0730-85f8-8f0e-c2b8c8713515"></a><a name="section-7.7"></a><p></p>
<h2><span class="Bold">7.7 Antimycobacterials</span></h2>
<p class="First">Rifampin [see <span class="Bold">Clinical Pharmacology </span><span class="Bold"><a href="#PHARMACOKINETICS">(12.3)</a></span>] and rifabutin are inducers of CYP3A enzymes and may decrease tacrolimus whole blood concentrations. Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when these antimycobacterial drugs and tacrolimus are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8ad9a415-701e-7800-3903-e16da4a8bf9c"></a><a name="section-7.8"></a><p></p>
<h2><span class="Bold">7.8 Anticonvulsants</span></h2>
<p class="First">Phenytoin, carbamazepine and phenobarbital induce CYP3A enzymes and may decrease tacrolimus whole blood concentrations. Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when these drugs and tacrolimus are used concomitantly. </p>
<p>Concomitant administration of phenytoin with tacrolimus may also increase phenytoin plasma concentrations. Thus, frequent monitoring phenytoin plasma concentrations and adjusting the phenytoin dose as needed are recommended when tacrolimus and phenytoin are administered concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_35b21cda-e072-788a-1538-c4874e89de0d"></a><a name="section-7.9"></a><p></p>
<h2><span class="Bold">7.9 St. John’s Wort (Hypericum perforatum)</span></h2>
<p class="First">St. John’s Wort induces CYP3A enzymes and may decrease tacrolimus whole blood concentrations. Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when St. John’s Wort and tacrolimus are co-administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_1e7b3454-f0c4-d842-0030-e633913f7c8c"></a><a name="section-7.10"></a><p></p>
<h2><span class="Bold">7.10 Gastric Acid Suppressors/Neutralizers</span></h2>
<p class="First">Lansoprazole and omeprazole, as CYP2C19 and CYP3A4 substrates, may potentially inhibit the CYP3A4 metabolism of tacrolimus and thereby substantially increase tacrolimus whole blood concentrations, especially in transplant patients who are intermediate or poor CYP2C19 metabolizers, as compared to those patients who are efficient CYP2C19 metabolizers.</p>
<p>Cimetidine may also inhibit the CYP3A4 metabolism of tacrolimus and thereby substantially increase tacrolimus whole blood concentrations.</p>
<p>Coadministration with magnesium and aluminum hydroxide antacids increase tacrolimus whole blood concentrations [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when these drugs and tacrolimus are used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_992ba1f7-d3bc-89cf-e06c-92725ca1027f"></a><a name="section-7.11"></a><p></p>
<h2><span class="Bold">7.11 Others</span></h2>
<p class="First">Bromocriptine, nefazodone, metoclopramide, danazol, ethinylestradiol, amiodarone, methylprednisolone and herbal productscontaining schisandra sphenanthera extracts may inhibit CYP3Ametabolism of tacrolimus and increase tacrolimus whole bloodconcentrations. Monitoring of blood concentrations andappropriate dosage adjustments of tacrolimus are recommendedwhen these drugs and tacrolimus are co-administered.and herbal productscontaining schisandra sphenanthera extracts may inhibit CYP3Ametabolism of tacrolimus and increase tacrolimus whole bloodconcentrations. Monitoring of blood concentrations andappropriate dosage adjustments of tacrolimus are recommendedwhen these drugs and tacrolimus are co-administered.may inhibit CYP3Ametabolism of tacrolimus and increase tacrolimus whole bloodconcentrations. Monitoring of blood concentrations andappropriate dosage adjustments of tacrolimus are recommendedwhen these drugs and tacrolimus are co-administered.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="USE_IN_SPECIFIC_POPULATIONS"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42228-7">
<a name="PREGNANCY"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C - There are no adequate and well-controlled studies in pregnant women. Tacrolimus is transferred across the placenta. The use of tacrolimus during pregnancy in humans has been associated with neonatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and renal dysfunction. Tacrolimus given orally to pregnant rabbits at 0.5 to 4.3 times the clinical dose and pregnant rats at 0.8 to 6.9 times the clinical dose was associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> in utero, <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (cardiovascular, skeletal, <span class="product-label-link" type="condition" conceptid="4077297" conceptname="Congenital omphalocele">omphalocele</span>, and gallbladder agenesis) and maternal toxicity. Tacrolimus should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.</p>
<p>In pregnant rabbits, tacrolimus at oral doses of 0.32 and 1.0 mg/kg, 0.5 to 4.3 times the clinical dose range (0.075  to 0.2 mg/kg) based on body surface area, was associated with maternal toxicity as well as an increased incidence of abortions. At the 1 mg/kg dose, fetal rabbits showed an increased incidence of malformations (ventricular hypoplasia, interventricular septal defect, bulbous aortic arch, stenosis of ductus arteriosus, interrupted ossification of vertebral arch, vertebral and rib malformations, <span class="product-label-link" type="condition" conceptid="4077297" conceptname="Congenital omphalocele">omphalocele</span>, and gallbladder agenesis) and developmental variations. In pregnant rats, tacrolimus at oral doses of 3.2 mg/kg, 2.6 to 6.9 times the clinical dose range was associated with maternal toxicity, an increase in late resorptions, decreased numbers of live births, and decreased pup weight and viability. Tacrolimus, given orally to pregnant rats after organogenesis and during lactation at 1.0 and 3.2 mg/kg, 0.8 to 6.9 times the recommended clinical dose range was associated with reduced pup weights and pup viability (3.2 mg/kg only); among the high dose pups that died early, an increased incidence of kidney <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span> was observed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="NURSING_MOTHERS"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Tacrolimus is excreted in human milk. As the effect of chronic exposure to tacrolimus in healthy infants is not established, patients maintained on tacrolimus should discontinue nursing taking into consideration importance of drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="PEDIATRIC_USE"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of tacrolimus in pediatric kidney and heart transplant patients have not been established. Successful liver transplants have been performed in pediatric patients (ages up to 16 years) using tacrolimus. Two randomized active controlled trials of tacrolimus in primary liver transplantation included 56 pediatric patients. Thirty-one patients were randomized to tacrolimus-based and 25 to cyclosporine-based therapies. Additionally, a minimum of 122 pediatric patients were studied in an uncontrolled trial of tacrolimus in living related donor liver transplantation. Pediatric patients generally required higher doses of tacrolimus to maintain blood trough concentrations of tacrolimus similar to adult patients [see <span class="Bold">Dosage and Administration <a href="#_3a7605f6-5634-6ab3-4d4c-1279ce614f23">(2.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="GERIATRIC_USE"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of tacrolimus did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_832ba428-c534-9139-0837-d637e38193bc"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.6 Use in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First">The pharmacokinetics of tacrolimus in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was similar to that in healthy volunteers with normal renal function. However, consideration should be given to dosing tacrolimus at the lower end of the therapeutic dosing range in patients who have received a liver or heart transplant and have pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Further reductions in dose below the targeted range may be required [see <span class="Bold">Dosage and Administration <a href="#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4">(2.3)</a> and Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_e0570a1e-c88a-34a9-de3e-66b1375da927"></a><a name="section-8.6"></a><p></p>
<h2><span class="Bold">8.7 Use in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First">The mean clearance of tacrolimus was substantially lower in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (mean Child-Pugh score: &gt;10) compared to healthy volunteers with normal hepatic function. Close monitoring of tacrolimus trough concentrations is warranted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>].</p>
<p>The use of tacrolimus in liver transplant recipients experiencing post-transplant <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may be associated with increased risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> related to high whole-blood trough concentrations of tacrolimus. These patients should be monitored closely and dosage adjustments should be considered. Some evidence suggests that lower doses should be used in these patients [see <span class="Bold">Dosage and Administration <a href="#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4">(2.3)</a> and Clinical Pharmacology </span><span class="Bold"><a href="#PHARMACOKINETICS">(12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OVERDOSAGE"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Limited overdosage experience is available. Acute overdosages of up to 30 times the intended dose have been reported. Almost all cases have been asymptomatic and all patients recovered with no sequelae. Acute overdosage was sometimes followed by adverse reactions consistent with those listed in <span class="Bold">Adverse Reactions </span><span class="Bold"><a href="#ADVERSE_REACTIONS">(6) </a></span>(including <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, abnormal renal function, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>); in one case of acute overdosage, transient <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> were observed. Based on the poor aqueous solubility and extensive erythrocyte and plasma protein binding, it is anticipated that tacrolimus is not dialyzable to any significant extent; there is no experience with charcoal hemoperfusion. The oral use of activated charcoal has been reported in treating <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span>, but experience has not been sufficient to warrant recommending its use. General supportive measures and treatment of specific symptoms should be followed in all cases of overdosage. </p>
<p>In acute oral and IV toxicity studies, mortalities were seen at or above the following doses: in adult rats, 52 times the recommended human oral dose; in immature rats, 16 times the recommended oral dose; and in adult rats, 16 times the recommended human IV dose (all based on body surface area corrections).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DESCRIPTION"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Tacrolimus USP is available for oral administration as capsules containing the equivalent of 0.5 mg, 1 mg or 5 mg of anhydrous tacrolimus. Inactive ingredients include croscarmellose sodium, lactose monohydrate and magnesium stearate. The 0.5 mg capsule shell contains gelatin, iron oxide red, iron oxide yellow and titanium dioxide, the 1 mg capsule shell contains gelatin and titanium dioxide and the 5 mg capsule shell contains gelatin, iron oxide red, iron oxide black, and titanium dioxide.</p>
<p>Tacrolimus USP, previously known as FK506, is the active ingredient in tacrolimus capsules USP. Tacrolimus USP is a macrolide immunosuppressant produced by <span class="Italics">Streptomyces tsukubaensis</span>. Chemically, tacrolimus USP is designated as [3S-[3R*[E(1S*,3S*,4S*)], 4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]] -5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, monohydrate.</p>
<p>The chemical structure of tacrolimus is:</p>
<p></p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=structure.jpg"></p>
<p>Tacrolimus USP has an empirical formula of C<span class="Sub">44</span>H<span class="Sub">69</span>NO<span class="Sub">12</span>•H<span class="Sub">2</span>O and a formula weight of 822.03. Tacrolimus USP appears as white to off white granular powder. It is practically insoluble in water, freely soluble in methanol, ethanol, acetone, ehyl acetate, chloroform. </p>
<p>Tacrolimus Capsules meets USP Organic Impurities Test <span class="Italics">Procedure 2.</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL_PHARMACOLOGY"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="43679-0">
<a name="MECHANISM_OF_ACTION"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Tacrolimus inhibits T-lymphocyte activation, although the exact mechanism of action is not known. Experimental evidence suggests that tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin inhibited. This effect may prevent the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines (such as interleukin-2, gamma interferon). The net result is the inhibition of T-lymphocyte activation (i.e., <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>).</p>
<p>Tacrolimus prolongs the survival of the host and transplanted graft in animal transplant models of liver, kidney, heart, bone marrow, small bowel and pancreas, lung and trachea, skin, cornea, and limb.</p>
<p>In animals, tacrolimus has been demonstrated to suppress some humoral immunity and, to a greater extent, cell-mediated reactions such as allograft rejection, <span class="product-label-link" type="condition" conceptid="4101555" conceptname="Cell-mediated immune reaction">delayed type hypersensitivity</span>, collagen-induced <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, experimental allergic <span class="product-label-link" type="condition" conceptid="373189" conceptname="Encephalomyelitis">encephalomyelitis</span>, and <span class="product-label-link" type="condition" conceptid="443216" conceptname="Graft versus host disease">graft versus host disease</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="PHARMACOKINETICS"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Tacrolimus activity is primarily due to the parent drug. The pharmacokinetic parameters (mean±S.D.) of tacrolimus have been determined following intravenous (IV) and/or oral (PO) administration in healthy volunteers, and in kidney transplant, liver and heart transplant patients (Table 14).</p>
<p><span class="Bold">Table 14. Pharmacokinetics Parameters (mean±S.D.) of Tacrolimus in Healthy Volunteers and Patients</span></p>
<p><span class="Bold"></span></p>
<table border="1" cellpadding="3" cellspacing="" width="85%"><tbody class="Headless">
<tr class="First">
<td><span class="Bold">Population </span></td>
<td><span class="Bold">N </span></td>
<td><span class="Bold">Route (Dose) </span></td>
<td><span class="Bold">Parameters</span></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C<span class="Sub">max</span> (ng/mL)</td>
<td>T<span class="Sub">max</span> (hr)</td>
<td>AUC (ng•hr/mL)</td>
<td>t<span class="Sub">1/2</span> (hr)</td>
<td>CI (L/hr/kg)</td>
<td>V (L/kg)</td>
</tr>
<tr>
<td>Healthy Volunteers</td>
<td>8</td>
<td>IV(0.025 mg/kg/4hr)</td>
<td>a</td>
<td>a</td>
<td>598<span class="Sup">b</span> ± 125 </td>
<td>34.2 ± 7.7</td>
<td>0.040 ± 0.009</td>
<td>1.91 ± 0.31</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>PO(5 mg)</td>
<td>29.7 ± 7.2</td>
<td>1.6 ± 0.7</td>
<td>243<span class="Sup">c</span> ± 73 </td>
<td>34.8 ± 11.4</td>
<td>0.041<span class="Sup">d</span> ± 0.008</td>
<td>1.94<span class="Sup">d</span> ± 0.53</td>
</tr>
<tr>
<td>Kidney Transplant Patients </td>
<td>26 </td>
<td>IV(0.02 mg/kg/12 hr)</td>
<td>a</td>
<td>a</td>
<td>294<span class="Sup">e</span> ± 262</td>
<td>18.8 ± 16.7</td>
<td>0.083 ± 0.050</td>
<td>1.41 ± 0.66</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td>PO(0.2 mg/kg/day)</td>
<td>19.2 ± 10.3</td>
<td>3.0</td>
<td>203<span class="Sup">e</span> ± 42</td>
<td>f</td>
<td>f</td>
<td>f</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td>PO(0.3 mg/kg/day)</td>
<td>24.2 ± 15.8</td>
<td>1.5</td>
<td>288<span class="Sup">e</span> ± 93</td>
<td>f</td>
<td>f</td>
<td>f</td>
</tr>
<tr>
<td>Liver Transplant Patients </td>
<td>17 </td>
<td>IV(0.05 mg/kg/12 hr)</td>
<td>a</td>
<td>a</td>
<td>3300<span class="Sup">e</span> ± 2130</td>
<td>11.7 ± 3.9</td>
<td>0.053 ± 0.017</td>
<td>0.85 ± 0.30</td>
</tr>
<tr>
<td> </td>
<td> </td>
<td>PO(0.3 mg/kg/day)</td>
<td>68.5 ± 30.0</td>
<td>2.3 ± 1.5</td>
<td>519<span class="Sup">e</span> ± 179</td>
<td>f</td>
<td>f</td>
<td>f</td>
</tr>
<tr>
<td>Heart Transplant Patients</td>
<td>11</td>
<td>IV (0.01 mg/kg/day as a continuous infusion)</td>
<td>a</td>
<td>a</td>
<td>954g ± 334</td>
<td>23.6 ± 9.22</td>
<td>0.051 ± 0.015</td>
<td>f</td>
</tr>
<tr>
<td> </td>
<td>11</td>
<td>PO (0.075 mg/kg/day)<span class="Sup">h</span>
</td>
<td>14.7 ± 7.79</td>
<td>2.1 [0.5-6.0]<span class="Sup">i</span>
</td>
<td>82.7j ± 63.2</td>
<td>a</td>
<td>f</td>
<td>f</td>
</tr>
<tr class="Last">
<td> </td>
<td>14</td>
<td>PO(0.15 mg/kg/day)<span class="Sup">h</span>
</td>
<td>24.5 ±13.7</td>
<td>1.5 [0.4-4.0]<span class="Sup">i</span>
</td>
<td>142<span class="Sup">j </span>± 116</td>
<td>a</td>
<td>f</td>
<td>f</td>
</tr>
</tbody></table>
<p>a) not applicable<span class="Sup"></span></p>
<p>b) AUC<span class="Sub">0-120</span><span class="Sup"></span></p>
<p>c) AUC<span class="Sub">0-72</span><span class="Sup"></span></p>
<p>d) Corrected for individual bioavailability<span class="Sup"></span></p>
<p>e) AUC<span class="Sub">0-inf</span><span class="Sup"></span></p>
<p>f) not available</p>
<p>g) AUC<span class="Sub">0-t</span></p>
<p>h) Determined after the first dose</p>
<p>i) Median [range]</p>
<p>j) AUC<span class="Sub">0-12</span></p>
<p>Due to intersubject variability in tacrolimus pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy [see <span class="Bold">Dosage and Administration (2.6)</span>]. Pharmacokinetic data indicate that whole blood concentrations rather than plasma concentrations serve as the more appropriate sampling compartment to describe tacrolimus pharmacokinetics.</p>
<p>Absorption</p>
<p>Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability of tacrolimus was 17±10% in adult kidney transplant patients (N=26), 22±6% in adult liver transplant patients (N=17), 23±9% in adult heart transplant patients (N=11) and 18±5% in healthy volunteers (N=16). </p>
<p>A single dose trial conducted in 32 healthy volunteers established the bioequivalence of the 1 mg and 5 mg capsules. Another single dose trial in 32 healthy volunteers established the bioequivalence of the 0.5 mg and 1 mg capsules. Tacrolimus maximum blood concentrations (C<span class="Sub">max</span>) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. </p>
<p>In 18 kidney transplant patients, tacrolimus trough concentrations from 3 to 30 ng/mL measured at 10 to 12 hours post-dose (C<span class="Sub">min</span>) correlated well with the AUC (correlation coefficient 0.93). In 24 liver transplant patients over a concentration range of 10 to 60 ng/mL, the correlation coefficient was 0.94.  In 25 heart transplant patients over a concentration range of 2 to 24 ng/mL, the correlation coefficient was 0.89 after an oral dose of 0.075 or 0.15 mg/kg/day at steady-state.</p>
<p>Food Effects</p>
<p>The rate and extent of tacrolimus absorption were greatest under fasted conditions. The presence and composition of food decreased both the rate and extent of tacrolimus absorption when administered to 15 healthy volunteers. </p>
<p>The effect was most pronounced with a high-fat meal (848 kcal, 46% fat): mean AUC and C<span class="Sub">max</span> were decreased 37% and 77%, respectively; T<span class="Sub">max</span> was lengthened 5-fold. A high-carbohydrate meal (668 kcal, 85% carbohydrate) decreased mean AUC and mean C<span class="Sub">max</span> by 28% and 65%, respectively.</p>
<p>In healthy volunteers (N=16), the time of the meal also affected tacrolimus bioavailability. When given immediately following the meal, mean C<span class="Sub">max</span> was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition.</p>
<p>When administered 1.5 hours following the meal, mean C<span class="Sub">max</span> was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition.</p>
<p><span class="Bold"></span>In 11 liver transplant patients, tacrolimus administered 15 minutes after a high fat (400 kcal, 34% fat) breakfast, resulted in decreased AUC (27±18%) and C<span class="Sub">max</span> (50±19%), as compared to a fasted state.</p>
<p>Tacrolimus capsules should be taken consistently every day either with or without food because the presence and composition of food decreases the bioavailability of tacrolimus [see<span class="Bold"> Dosage and Administration </span><span class="Bold"><a href="#_f4e10115-ade6-2ded-a674-e5294ba195be">(2.5)</a></span>].</p>
<p>Distribution</p>
<p>The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5 to 50 ng/mL. Tacrolimus is bound mainly to albumin and alpha-1-acid glycoprotein, and has a high level of association with erythrocytes. The distribution of tacrolimus between whole blood and plasma depends on several factors, such as hematocrit, temperature at the time of plasma separation, drug concentration, and plasma protein concentration. In a U.S. trial, the ratio of whole blood concentration to plasma concentration averaged 35 (range 12 to 67).</p>
<p>Metabolism</p>
<p>Tacrolimus is extensively metabolized by the mixed-function oxidase system, primarily the cytochrome P-450 system (CYP3A). A metabolic pathway leading to the formation of 8 possible metabolites has been proposed. Demethylation and hydroxylation were identified as the primary mechanisms of biotransformation in vitro. The major metabolite identified in incubations with human liver microsomes is 13-demethyl tacrolimus. In in vitro studies, a 31-demethyl metabolite has been reported to have the same activity as tacrolimus.</p>
<p>Excretion</p>
<p>The mean clearance following IV administration of tacrolimus is 0.040, 0.083, 0.053 and 0.051 L/hr/kg in healthy volunteers, adult kidney transplant patients, adult liver transplant patients, and adult heart transplant patients, respectively. In man, less than 1% of the dose administered is excreted unchanged in urine. </p>
<p>In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study of IV administered radiolabeled tacrolimus to 6 healthy volunteers, the mean recovery of radiolabel was 77.8±12.7%. Fecal elimination accounted for 92.4±1.0% and the elimination half-life based on radioactivity was 48.1±15.9 hours whereas it was 43.5±11.6 hours based on tacrolimus concentrations. The mean clearance of radiolabel was 0.029±0.015 L/hr/kg and clearance of tacrolimus was 0.029±0.009 L/hr/kg. When administered PO, the mean recovery of the radiolabel was 94.9±30.7%. Fecal elimination accounted for 92.6±30.7%, urinary elimination accounted for 2.3±1.1% and the elimination half-life based on radioactivity was 31.9±10.5 hours whereas it was 48.4±12.3 hours based on tacrolimus concentrations. The mean clearance of radiolabel was 0.226±0.116 L/hr/kg and clearance of tacrolimus 0.172±0.088 L/hr/kg.</p>
<p><span class="Bold">Specific Populations</span></p>
<p>Pediatric</p>
<p>Pharmacokinetics of tacrolimus have been studied in liver transplantation patients, 0.7 to 13.2 years of age. Following IV administration of a 0.037 mg/kg/day dose to 12 pediatric patients, mean terminal half-life, volume of distribution and clearance were 11.5±3.8 hours, 2.6±2.1 L/kg and 0.138±0.071 L/hr/kg, respectively. Following oral administration to 9 patients, mean AUC and C<span class="Sub">max</span> were 337±167 ng·hr/mL and 48.4±27.9 ng/mL, respectively. The absolute bioavailability was 31±24%.</p>
<p>Whole blood trough concentrations from 31 patients less than 12 years old showed that pediatric patients needed higher doses than adults to achieve similar tacrolimus trough concentrations [see <span class="Bold">Dosage and Administration </span><span class="Bold"><a href="#_3a7605f6-5634-6ab3-4d4c-1279ce614f23">(2.2)</a></span>].</p>
<p>Pharmacokinetics of tacrolimus have also been studied in kidney transplantation patients, 8.2±2.4 years of age. Following IV infusion of a 0.06 (range 0.06 to 0.09) mg/kg/day to 12 pediatric patients (8 male and 4 female), mean terminal half-life and clearance were 10.2±5.0 (range 3.4 to 25) hours and 0.12±0.04 (range 0.06 to 0.17) L/hr/kg, respectively. Following oral administration to the same patients, mean AUC and C<span class="Sub">max</span> were 181±65 (range 81 to 300) ng·hr/mL and 30±11 (range 14 to 49) ng/mL, respectively. The absolute bioavailability was 19±14 (range 5.2 to 56) %. </p>
<p>Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></p>
<p>The mean pharmacokinetic parameters for tacrolimus following single administrations to patients with renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> are given in Table 15.</p>
<p><span class="Bold">Table 15. Pharmacokinetic In Renal and Hepatic Impaired Patients</span></p>
<table border="1" cellpadding="4" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td valign="top">
<span class="Bold">Population </span><span class="Bold">(No. of Patients) </span>
</td>
<td valign="top"><span class="Bold">Dose</span></td>
<td valign="top">
<span class="Bold">AUC<span class="Sub">0-t </span></span><br><span class="Bold">(ng·hr/mL)</span>
</td>
<td valign="top">
<span class="Bold">t<span class="Sub">1/2</span></span><span class="Bold">(hr)</span>
</td>
<td valign="top">
<span class="Bold">V</span><span class="Bold">(L/kg)</span>
</td>
<td valign="top">
<span class="Bold">CI</span><span class="Bold">(L/hr/kg)</span>
</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (n=12) </td>
<td valign="top">0.02 mg/kg/4hr<br>IV</td>
<td valign="top">393±123 <br>(t=60 hr)</td>
<td valign="top">26.3 ±9.2</td>
<td valign="top">1.07±0.20</td>
<td valign="top">0.038±0.014</td>
</tr>
<tr>
<td rowspan="2" valign="top">Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (n=6) </td>
<td valign="top">0.02 mg/kg/4hr <br>IV</td>
<td valign="top">367±107 <br>(t=72 hr)</td>
<td valign="top">60.6±43.8 <br>Range: <br>27.8 to 141</td>
<td valign="top">3.1±1.6</td>
<td valign="top">0.042±0.02</td>
</tr>
<tr>
<td valign="top">7.7 mg <br>PO</td>
<td valign="top">488±320 <br>(t=72 hr)</td>
<td valign="top">66.1±44.8 <br>Range: <br>29.5 to 138</td>
<td valign="top">3.7±4.7<span class="Sup">a</span>
</td>
<td valign="top">0.034±0.019<span class="Sup">a</span>
</td>
</tr>
<tr>
<td>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (n=6, IV)</td>
<td>0.02 mg/kg/4hr <br>IV (n=2) <br>0.01 mg/kg/8hr <br>IV (n=4)</td>
<td>762±204<br>(t=120 hr) <br>289±117<br>(t=144 hr)</td>
<td>198±158 <br>Range:<br>81 to 436</td>
<td>3.9±1.0</td>
<td>0.017±0.013</td>
</tr>
<tr>
<td valign="top">(n=5, PO)<span class="Sup">b</span>
</td>
<td>8 mg PO <br>(n=1)</td>
<td>658<br>(t=120 hr)</td>
<td>119±35 <br>Range:<br>85 to 178</td>
<td>3.1±3.4<span class="Sup">a</span>
</td>
<td>0.016±0.011<span class="Sup">a</span>
</td>
</tr>
<tr class="Last">
<td valign="top"> </td>
<td valign="top">5 mg PO<br>(n=4) <br>4 mg PO <br>(n=1)</td>
<td valign="top">533±156 <br>(t=144 hr)</td>
<td valign="top"> </td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
</tbody></table>
<p><span class="Sup"></span>a) corrected for bioavailability<span class="Sup"></span></p>
<p>b) 1 patient did not receive the PO dose</p>
<p><span class="Bold"></span><span class="Bold"></span></p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Tacrolimus pharmacokinetics following a single IV administration were determined in 12 patients (7 not on dialysis and 5 on dialysis, serum creatinine of 3.9±1.6 and 12.0±2.4 mg/dL, respectively) prior to their kidney transplant. The pharmacokinetic parameters obtained were similar for both groups. The mean clearance of tacrolimus in patients with renal dysfunction was similar to that in normal volunteers (Table 15) [see <span class="Bold">Dosage and Administration <a href="#_a17eaea8-2b11-5d5e-1a25-2c8fd5dd78b4">(2.3)</a> and Use in Specific Populations <a href="#_832ba428-c534-9139-0837-d637e38193bc">(8.6)</a></span>].</p>
<p><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Tacrolimus pharmacokinetics have been determined in six patients with mild hepatic dysfunction (mean Pugh score: 6.2) following single IV and oral administrations. The mean clearance of tacrolimus in patients with mild hepatic dysfunction was not substantially different from that in normal volunteers (see previous table). Tacrolimus pharmacokinetics were studied in 6 patients with severe hepatic dysfunction (mean Pugh score: &gt;10). The mean clearancewas substantially lower in patients with severe hepatic dysfunction, irrespective of the route of administration [see <span class="Bold">Dosage and Administration <a href="#_59b20539-7308-91d8-2ed0-31decab6ad6c">(2.4)</a> and Use in Specific Populations </span><span class="Bold"><a href="#_e0570a1e-c88a-34a9-de3e-66b1375da927">(8.7)</a></span>].</p>
<p>RaceThe pharmacokinetics of tacrolimus have been studied following single IV and oral administration of tacrolimus to 10 African-American, 12 Latino-American, and 12 Caucasian healthy volunteers. There were no significant pharmacokinetic differences among the three ethnic groups following a 4-hour IV infusion of 0.015 mg/kg. However, after single oral administration of 5 mg, mean (±SD) tacrolimus C<span class="Sub">max</span> in African-Americans (23.6±12.1 ng/mL) was significantly lower than in Caucasians (40.2±12.6 ng/mL) and the Latino-Americans (36.2±15.8 ng/mL) (p&lt;0.01).  Mean AUC<span class="Sub">0-inf</span> tended to be lower in African-Americans (203±115 ng·hr/mL) than Caucasians (344±186 ng·hr/mL) and Latino- Americans (274±150 ng·hr/mL). The mean (±SD) absolute oral bioavailability (F) in African-Americans (12±4.5%) and Latino-Americans (14±7.4%) was significantly lower than in Caucasians (19±5.8%, p=0.011). There was no significant difference in mean terminal T<span class="Sub">1/2</span> among the three ethnic groups (range from approximately 25 to 30 hours). A retrospective comparison of African-American and Caucasian kidney transplant patients indicated that African-American patients required higher tacrolimus doses to attain similar trough concentrations [see <span class="Bold">Dosage and Administration </span><span class="Bold"><a href="#_c727e851-a3c1-9956-661d-4f6786df4434">(2.1)</a></span>].</p>
<p>GenderA formal trial to evaluate the effect of gender on tacrolimus pharmacokinetics has not been conducted, however, there was no difference in dosing by gender in the kidney transplant trial. A retrospective comparison of pharmacokinetics in healthy volunteers, and in kidney and liver transplant patients indicated no gender-based differences.</p>
<p><span class="Bold">Drug Interactions</span><span class="Bold"></span></p>
<p>Frequent monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when concomitant use of the following drugs with tacrolimus is initiated or discontinued [see <span class="Bold">Drug Interactions <a href="#DRUG_INTERACTIONS">(7)</a></span>].</p>
<p>Telaprevir: In a single dose study in 9 healthy volunteers, coadministration of tacrolimus (0.5 mg single dose) with telaprevir (750 mg three times daily for 13 days) increased the tacrolimus dose-normalized C<span class="Sub">max</span> by 9.3-fold and AUC by 70-fold compared to tacrolimus alone [see <span class="Bold">Drug Interactions </span><span class="Bold"><a href="#_3447c8d3-0e24-1461-e6b5-a4f7a84bd9d7">(7.3)</a></span>].</p>
<p>Boceprevir: In a single dose study in 12 subjects, coadministration of tacrolimus (0.5 mg single dose) with boceprevir (800 mg three times daily for 11 days) increased tacrolimus C<span class="Sub">max</span> by 9.9-fold and AUC by 17-fold compared to tacrolimus alone [see <span class="Bold">Drug Interactions </span><span class="Bold"><a href="#_3447c8d3-0e24-1461-e6b5-a4f7a84bd9d7">(7.3)</a></span>].</p>
<p>Nelfinavir: Based on a clinical study of 5 liver transplant recipients, co-administration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL. It is recommended to avoid concomitant use of tacrolimus and nelfinavir unless the benefits outweigh the risks [see <span class="Bold">Drug Interactions </span><span class="Bold"><a href="#_3447c8d3-0e24-1461-e6b5-a4f7a84bd9d7">(7.3)</a></span>].</p>
<p>Rifampin: In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (14±6% vs. 7±3%) was observed with concomitant rifampin administration (600 mg). In addition, there was a significant increase in tacrolimus clearance (0.036±0.008 L/hr/kg vs. 0.053±0.010 L/hr/kg) with concomitant rifampin administration [see <span class="Bold">Drug Interactions (<a href="#_36fabc49-0730-85f8-8f0e-c2b8c8713515">7.7)</a></span>].</p>
<p>Magnesium-aluminum-hydroxide: In a single-dose crossover study in healthy volunteers, co-administration of tacrolimus and magnesium-aluminum-hydroxide resulted in a 21% increase in the mean tacrolimus AUC and a 10% decrease in the mean tacrolimus C<span class="Sub">max</span> relative to tacrolimus administration alone [see<span class="Bold"> Drug Interactions <a href="#_1e7b3454-f0c4-d842-0030-e633913f7c8c">(7.10</a>)</span>].</p>
<p>Ketoconazole: In a study of 6 normal volunteers, a significant increase in tacrolimus oral bioavailability (14±5% vs. 30±8%) was observed with concomitant ketoconazole administration (200 mg). The apparent oral clearance of tacrolimus during ketoconazole administration was significantly decreased compared to tacrolimus alone (0.430±0.129 L/hr/kg vs. 0.148±0.043 L/hr/kg). Overall, IV clearance of tacrolimus was not significantly changed by ketoconazole coadministration, although it was highly variable between patients [see <span class="Bold">Drug Interactions <a href="#_ff7f9ee1-7369-84a6-6e82-2f2ed520c272">(7.4</a>)</span>].</p>
<p>Voriconazole (see complete prescribing information for VFEND<span class="Sup">®)</span>: Repeat oral dose administration of voriconazole (400 mg every 12 hours for one day, then 200 mg every 12 hours for 6 days) increased tacrolimus (0.1 mg/kg single dose) C<span class="Sub">max</span> and AUC<span class="Sub">τ</span> in healthy subjects by an average of 2-fold (90% CI: 1.9, 2.5) and 3-fold (90% CI: 2.7, 3.8), respectively [see <span class="Bold">Drug Interactions (<a href="#_ff7f9ee1-7369-84a6-6e82-2f2ed520c272">7.4)</a></span>].</p>
<p>Posaconazole (see complete prescribing information for Noxafil<span class="Sup">®</span>): Repeat oral administration of posaconazole (400 mg twice daily for 7 days) increased tacrolimus (0.05 mg/kg single dose) C<span class="Sub">max</span> and AUC in healthy subjects by an average of 2-fold (90% CI: 2.01, 2.42) and 4.5-fold (90% CI 4.03, 5.19), respectively [see <span class="Bold">Drug Interactions (<a href="#_ff7f9ee1-7369-84a6-6e82-2f2ed520c272">7.4)</a></span>].<span class="Bold"></span></p>
<p>Caspofungin (see complete prescribing information for CANCIDAS<span class="Sup">®</span>): Caspofungin reduced the blood AUC<span class="Sub">0-12</span> of tacrolimus by approximately 20%, peak blood concentration (C<span class="Sub">max</span>) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy adult subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS<span class="Sup">®</span> 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone [see <span class="Bold">Drug Interactions <a href="#_ff7f9ee1-7369-84a6-6e82-2f2ed520c272">(7.4)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="NONCLINICAL_TOXICOLOGY"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34083-6">
<a name="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</h2>
<p class="First">Carcinogenicity studies were conducted in male and female rats and mice. In the 80-week mouse oral study and in the 104-week rat oral study, no relationship of tumor incidence to tacrolimus dosage was found. The highest dose used in the mouse was 3 mg/kg/day (0.9 to 2.2 times the AUC at clinical doses of 0.075 to 0.2 mg/kg/day) and in the rat was 5 mg/kg/day (0.265 to 0.65 times the AUC at clinical doses of 0.075 to 0.2 mg/kg/day) [see<a href="#BOXED_WARNING"></a><span class="Bold"><a href="#BOXED_WARNING">Boxed Warning</a></span> and<span class="Bold"><a href="#_c1430800-6a47-a6a5-a2eb-d70663158c0e"> Warnings and Precautions (5.2)</a></span>]. </p>
<p>A 104-week dermal carcinogenicity study was performed in mice with tacrolimus ointment (0.03% to 3%), equivalent to tacrolimus doses of 1.1 to 118 mg/kg/day or 3.3 to 354 mg/m<span class="Sup">2</span>/day. In the study, the incidence of <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> was minimal and the topical application of tacrolimus was not associated with <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumor</span> formation under ambient room lighting. However, a statistically significant elevation in the incidence of pleomorphic <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> in high dose male (25/50) and female animals (27/50) and in the incidence of undifferentiated <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> in high dose female animals (13/50) was noted in the mouse dermal carcinogenicity study. <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphomas</span> were noted in the mouse dermal carcinogenicity study at a daily dose of 3.5 mg/kg (0.1% tacrolimus ointment). No drug-related tumors were noted in the mouse dermal carcinogenicity study at a daily dose of 1.1 mg/kg (0.03% tacrolimus ointment). The relevance of topical administration of tacrolimus in the setting of systemic tacrolimus use is unknown. </p>
<p>The implications of these carcinogenicity studies to the human condition are limited; doses of tacrolimus were administered that likely induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in these animals impairing their immune system’s ability to inhibit unrelated carcinogenesis.</p>
<p>No evidence of genotoxicity was seen in bacterial (<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> and <span class="Italics">E. coli</span>) or mammalian (Chinese hamster lung-derived cells) <span class="Italics">in vitro</span> assays of mutagenicity, the <span class="Italics">in vitro</span> CHO/HGPRT assay of mutagenicity, or in vivo clastogenicity assays performed in mice; tacrolimus did not cause unscheduled DNA synthesis in rodent hepatocytes.</p>
<p>Tacrolimus given orally at 1.0 mg/kg (0.8 to 2.2 times the clinical dose range of 0.075 to 0.2 mg/kg/day based on body surface area) to male and female rats, prior to and during mating, as well as to dams during gestation and lactation, was associated with embryolethality and adverse effects on female reproduction. Effects on female reproductive function (parturition) and embryolethal effects were indicated by a higher rate of pre-implantation loss and increased numbers of undelivered and nonviable pups. When given at 3.2 mg/kg (2.6 to 6.9 times the clinical dose range based on body surface area), tacrolimus was associated with maternal and paternal toxicity as well as reproductive toxicity including marked adverse effects on estrus cycles, parturition, pup viability, and pup malformations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CLINICAL_STUDIES"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_df213488-e1ee-4264-95f9-0422aedfd287"></a><a name="section-13.1"></a><p></p>
<h2><span class="Bold">14.1 Kidney Transplantation</span></h2>
<p class="First">Tacrolimus/azathioprine (AZA)</p>
<p>Tacrolimus-based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in conjunction with azathioprine and corticosteroids following kidney transplantation was assessed in a randomized, multicenter, non-blinded, prospective trial. There were 412 kidney transplant patients enrolled at 19 clinical sites in the United States. Study therapy was initiated when renal function was stable as indicated by a serum creatinine ≤ 4 mg/dL (median of 4 days after transplantation, range 1 to 14 days). Patients less than 6 years of age were excluded.</p>
<p>There were 205 patients randomized to tacrolimus-based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> and 207 patients were randomized to cyclosporine-based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. All patients received <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> induction therapy consisting of an antilymphocyte antibody preparation, corticosteroids and azathioprine. Overall 1 year patient and graft survival was 96.1% and 89.6%, respectively.</p>
<p>Data from this trial of tacrolimus in conjunction with azathioprine indicate that during the first three months of that trial, 80% of the patients maintained trough concentrations between 7 to 20 ng/mL, and then between 5 to 15 ng/mL, through 1 year.</p>
<p>Tacrolimus/mycophenolate mofetil (MMF)</p>
<p>Tacrolimus-based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in conjunction with MMF, corticosteroids, and induction has been studied. In a randomized, open-label, multi-center trial (Study 1), 1589 kidney transplant patients received tacrolimus (Group C, n=401), sirolimus (Group D, n=399), or one of two cyclosporine (CsA) regimens (Group A, n=390 and Group B, n=399) in combination with MMF and corticosteroids; all patients, except those in one of the two cyclosporine groups, also receivedinduction with daclizumab. The trial was conducted outside the United States; the trial population was 93% Caucasian. In this trial, mortality at 12 months in patients receiving tacrolimus/MMF was similar (3%) compared to patients receiving cyclosporine/MMF (3% and 2%) or sirolimus/MMF (3%). Patients in the tacrolimus group exhibited higher estimated creatinine clearance rates (eCLcr) using the Cockcroft-Gault formula (Table 16) and experienced fewer efficacy failures, defined as biopsy proven acute rejection (BPAR), graft loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and/or lost to follow-up (Table 17) in comparison to each of the other three groups. Patients randomized to tacrolimus/MMF were more likely to develop <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> after the transplantation and experienced similar rates of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> compared to patients randomized to either cyclosporine/MMF regimen [see <span class="Bold">Adverse Reactions <a href="#_54ee3c7f-7f29-3bfc-f5d3-cb4a64e144a2">(6.1</a>)</span>].</p>
<p><span class="Bold">Table 16. Estimated Creatinine Clearance at 12 Months (Study 1)</span></p>
<table border="1" cellpadding="3" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td rowspan="2" valign="top"><span class="Bold">Group </span></td>
<td colspan="5" valign="top"><span class="Bold">eCLcr [mL/min] at Month 12<span class="Sup">a</span></span></td>
</tr>
<tr>
<td valign="top"><span class="Bold">N </span></td>
<td valign="top"><span class="Bold">MEAN </span></td>
<td valign="top"><span class="Bold">SD </span></td>
<td valign="top"><span class="Bold">MEDIAN </span></td>
<td valign="top">
<span class="Bold">Treatment Difference with Group C </span><span class="Bold">(99.2% CI <span class="Sup">b</span>) </span>
</td>
</tr>
<tr>
<td align="left">(A) CsA/MMF/CS </td>
<td>390 </td>
<td>56.5 </td>
<td>25.8 </td>
<td>56.9 </td>
<td>-8.6 (-13.7, -3.7) </td>
</tr>
<tr>
<td align="left">(B) CsA/MMF/CS/Daclizuma<span class="Sup">b</span>
</td>
<td>399 </td>
<td>58.9 </td>
<td>25.6 </td>
<td>60.9 </td>
<td>-6.2 (-11.2, -1.2) </td>
</tr>
<tr>
<td align="left">(C) Tac/MMF/CS/Daclizuma<span class="Sup">b </span>
</td>
<td>401 </td>
<td>65.1 </td>
<td>27.4 </td>
<td>66.2 </td>
<td>-</td>
</tr>
<tr>
<td align="left">(D) Siro/MMF/CS/Daclizuma<span class="Sup">b</span>
</td>
<td>399 </td>
<td>56.2 </td>
<td>27.4 </td>
<td>57.3 </td>
<td>-8.9 (-14.1, -3.9) </td>
</tr>
<tr>
<td align="left">Total </td>
<td>1589 </td>
<td>59.2 </td>
<td>26.8 </td>
<td>60.5 </td>
<td valign="top"> </td>
</tr>
<tr class="Last"><td align="left" colspan="6">Key: CsA=Cyclosporine, CS=Corticosteroids, Tac=Tacrolimus, Siro=Sirolimus </td></tr>
</tbody></table>
<p>a) <span class="Sup"></span>All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>/graft loss (n=41, 27, 23 and 42 in Groups A, B, C and D) and patients whose last recorded creatinine values were prior to month 3 visit (n=10, 9, 7 and 9 in Groups A, B, C and D, respectively) were inputed with Glomerular Filtration Rate (GFR) of 10 mL/min; a subject's last observed creatinine value from month 3 on was used for the remainder of subjects with missing creatinine at month 12 (n=11, 12, 15 and 19 for Groups A, B, C and D, respectively). Weight was also imputed in the calculation of estimated GFR, if missing.</p>
<p><span class="Sup"></span>b) Adjusted for multiple (6) pairwise comparisons using Bonferroni corrections.</p>
<p><span class="Bold">Table 17. Incidence of BPAR, Graft Loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Loss to Follow-up at 12 Months (Study 1)</span></p>
<table border="1" cellpadding="3" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td valign="top"> </td>
<td><span class="Bold">Group A </span></td>
<td><span class="Bold">Group B </span></td>
<td><span class="Bold">Group C </span></td>
<td><span class="Bold">Group D </span></td>
</tr>
<tr>
<td valign="top"> </td>
<td><span class="Bold">N=390 </span></td>
<td><span class="Bold">N=399 </span></td>
<td><span class="Bold">N=401 </span></td>
<td><span class="Bold">N=399 </span></td>
</tr>
<tr>
<td align="left">Overall Failure </td>
<td>141 (36.2%) </td>
<td valign="top">126 (31.6%) </td>
<td valign="top">82 (20.4%) </td>
<td>185 (46.4%) </td>
</tr>
<tr>
<td align="left">Components of efficacy failure </td>
<td valign="top"> </td>
<td valign="top"> </td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td align="left">BPAR </td>
<td>113 (29.0%) </td>
<td>106 (26.6%) </td>
<td>60 (15.0%) </td>
<td>152 (38.1%) </td>
</tr>
<tr>
<td align="left" valign="top">Graft loss excluding <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td>28 (7.2%) </td>
<td>20 (5.0%) </td>
<td>12 (3.0%) </td>
<td>30 (7.5%) </td>
</tr>
<tr>
<td align="left">Mortality </td>
<td>13 (3.3%) </td>
<td>7 (1.8%) </td>
<td>11 (2.7%) </td>
<td>12 (3.0%) </td>
</tr>
<tr>
<td align="left">Lost to follow-up </td>
<td>5 (1.3%) </td>
<td>7 (1.8%) </td>
<td>5 (1.3%) </td>
<td>6 (1.5%) </td>
</tr>
<tr>
<td align="left">Treatment Difference of efficacy failure <br>compared to Group C (99.2% CI<span class="Sup">a</span>)</td>
<td>15.8% <br>(7.1%, 24.3%)</td>
<td>11.2%<br>(2.7%, 19.5%)  </td>
<td valign="top"> -</td>
<td>26.0% <br>(17.2%, 34.7%)</td>
</tr>
<tr class="Last"><td align="left" colspan="5">Key: Group A = CsA/MMF/CS, B = CsA/MMF/CS/Daclizumab, C = Tac/MMF/CS/Daclizumab, and D = Siro/MMF/CS/Daclizumab </td></tr>
</tbody></table>
<p><span class="Bold"></span></p>
<p><span class="Sup"></span>a) Adjusted for multiple (6) pairwise comparisons using Bonferroni corrections.</p>
<p>The protocol-specified target tacrolimus trough concentrations (C<span class="Sub">trough,Tac</span>) were 3 to 7 ng/mL; however, the observed median C<span class="Sub">troughs,Tac</span> approximated 7 ng/mL throughout the 12 month trial (Table 18). Approximately 80% of patients maintained tacrolimus whole blood concentrations between 4 to 11 ng/mL through 1 year post-transplant.</p>
<p><span class="Bold">Table 18. Tacrolimus Whole Blood Trough Concentrations (Study 1)</span></p>
<table border="1" cellpadding="03" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td valign="top"><span class="Bold">Time </span></td>
<td valign="top">
<span class="Bold">Median (P10 to P90<span class="Sup">a</span>) tacrolimus whole blood trough concentrations </span><br><span class="Bold">(ng/mL) </span>
</td>
</tr>
<tr>
<td>Day 30 (N=366) </td>
<td>6.9 (4.4 to 11.3) </td>
</tr>
<tr>
<td>Day 90 (N=351) </td>
<td>6.8 (4.1 to 10.7) </td>
</tr>
<tr>
<td>Day 180 (N=355) </td>
<td>6.5 (4.0 to 9.6) </td>
</tr>
<tr class="Last">
<td>Day 365 (N=346) </td>
<td>6.5 (3.8 to 10.0) </td>
</tr>
</tbody></table>
<p>a) 10 to 90<span class="Sup">th</span> Percentile: range of C<span class="Sub">trough, Tac</span> that excludes lowest 10% and highest 10% of C<span class="Sub">trough,Tac</span></p>
<p>The protocol-specified target cyclosporine trough concentrations (C<span class="Sub">trough,CsA</span>) for Group B were 50 to 100 ng/mL; however, the observed median C<span class="Sub">troughs,CsA</span> approximated 100 ng/mL throughout the 12 month trial. The protocol-specified target C<span class="Sub">troughs,CsA</span> for Group A were 150 to 300 ng/mL for the first 3 months and 100 to 200 ng/mL from month 4 to month 12; the observed median C<span class="Sub">troughs, CsA</span> approximated 225 ng/mL for the first 3 months and 140 ng/mL from month 4 to month 12.</p>
<p>While patients in all groups started MMF at 1gram twice daily, the MMF dose was reduced to less than 2 g per day in 63% of patients in the tacrolimus treatment arm by month 12 (Table 19); approximately 50% of these MMF dose reductions were due to adverse reactions. By comparison, the MMF dose was reduced to less than 2 g per day in 49% and 45% of patients in the two cyclosporine arms (Group A and Group B, respectively), by month 12 and approximately 40% of MMF dose reductions were due to adverse reactions.</p>
<p><span class="Bold">Table 19. MMF Dose Over Time in Tacrolimus/MMF (Group C) (Study 1)</span></p>
<table border="1" cellpadding="3" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td rowspan="2" valign="top"><span class="Bold">Time period (Days) </span></td>
<td colspan="4"><span class="Bold">Time-averaged MMF dose (grams per day)<span class="Sup">a</span></span></td>
</tr>
<tr>
<td>Less than 2.0</td>
<td>2.0</td>
<td>Greater than 2.0</td>
<td> </td>
</tr>
<tr>
<td align="left">0 to 30 (N=364) </td>
<td>37%</td>
<td>60%</td>
<td>2%</td>
<td> </td>
</tr>
<tr>
<td align="left">0 to 90 (N=373) </td>
<td>47%</td>
<td>51%</td>
<td>2%</td>
<td> </td>
</tr>
<tr>
<td align="left">0 to 180 (N=377) </td>
<td>56%</td>
<td>42%</td>
<td>2%</td>
<td> </td>
</tr>
<tr>
<td align="left">0 to 365 (N=380) </td>
<td>63%</td>
<td>36%</td>
<td>1%</td>
<td> </td>
</tr>
<tr class="Last"><td align="left" colspan="5">Key: Time-averaged MMF dose = (total MMF dose)/(duration of treatment) </td></tr>
</tbody></table>
<p>a) <span class="Sup"></span>Percentage of patients for each time-averaged MMF dose range during various treatment periods. Administration of 2 g per day of time-averaged MMF dose means that MMF dose was not reduced in those patients during the treatment periods.</p>
<p>In a second randomized, open-label, multi-center trial (Study 2), 424 kidney transplant patients received tacrolimus (N=212) or cyclosporine (N=212) in combination with MMF 1 gram twice daily, basiliximab induction, and corticosteroids. In this trial, the rate for the combined endpoint of BPAR, graft failure, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and/or lost to follow-up at 12 months in the tacrolimus/MMF group was similar to the rate in the cyclosporine/MMF group. There was, however, an imbalance in mortality at 12 months in those patients receiving tacrolimus/MMF (4%) compared to those receiving cyclosporine/MMF (2%), including cases attributed to overimmunosuppression (Table 20).</p>
<p><span class="Bold">Table 20. Incidence of BPAR, Graft Loss, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Loss to Follow-up at 12 Months (Study 2)</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="98%"><tbody class="Headless">
<tr class="First">
<td valign="top"> </td>
<td><span class="Bold">Tacrolimus/MMF </span></td>
<td><span class="Bold">Cyclosporine/MMF </span></td>
</tr>
<tr>
<td valign="top"> </td>
<td><span class="Bold">(N=212) </span></td>
<td><span class="Bold">(N=212) </span></td>
</tr>
<tr>
<td>Overall Failure </td>
<td>32 (15.1%) </td>
<td>36 (17.0%) </td>
</tr>
<tr>
<td>Components of efficacy failure </td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td>BPAR </td>
<td>16 (7.5%) </td>
<td>29 (13.7%) </td>
</tr>
<tr>
<td>Graft loss excluding <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </td>
<td>6 (2.8%) </td>
<td>4 (1.9%) </td>
</tr>
<tr>
<td>Mortality </td>
<td>9 (4.2%) </td>
<td>5 (2.4%) </td>
</tr>
<tr>
<td>Lost to follow-up </td>
<td>4 (1.9%) </td>
<td>1 (0.5%) </td>
</tr>
<tr>
<td>Treatment Difference of efficacy failure </td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr class="Last">
<td>compared to tacrolimus/MMF group (95% CI<span class="Sup">a</span>) </td>
<td valign="top"> </td>
<td valign="bottom">1.9% (-5.2%, 9.0%) </td>
</tr>
</tbody></table>
<p>a) <span class="Sup"></span>95% confidence interval calculated using Fisher's Exact Test </p>
<p>The protocol-specified target tacrolimus whole blood trough concentrations (C<span class="Sub">trough,Tac</span>) in Study 2 were 7 to 16 ng/mL for the first three months and 5 to 15 ng/mL thereafter. The observed median C<span class="Sub">troughs,Tac</span> approximated 10 ng/mL during the first three months and 8 ng/mL from month 4 to month 12 (Table 21). Approximately 80% of patients maintained tacrolimus whole trough blood concentrations between 6 to 16 ng/mL during months 1 through 3 and, then, between 5 to 12 ng/mL from month 4 through 1 year.</p>
<p><span class="Bold">Table 21. Tacrolimus Whole Blood Trough Concentrations (Study 2)</span></p>
<table border="1" cellpadding="3" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td valign="top"><span class="Bold">Time </span></td>
<td valign="top">
<span class="Bold">Median (P10 to P90<span class="Sup">a</span>) tacrolimus whole blood trough concentrations</span><br><span class="Bold"> (ng/mL) </span>
</td>
</tr>
<tr>
<td>Day 30 (N=174) </td>
<td>10.5 (6.3 to 16.8) </td>
</tr>
<tr>
<td>Day 60 (N=179) </td>
<td>9.2 (5.9 to 15.3) </td>
</tr>
<tr>
<td>Day 120 (N=176) </td>
<td>8.3 (4.6 to 13.3) </td>
</tr>
<tr>
<td>Day 180 (N=171) </td>
<td>7.8 (5.5 to 13.2) </td>
</tr>
<tr class="Last">
<td>Day 365 (N=178) </td>
<td>7.1 (4.2 to 12.4) </td>
</tr>
</tbody></table>
<p>a) <span class="Sup"></span>10 to 90<span class="Sup">th</span> Percentile: range of C<span class="Sub">trough,Tac</span> that excludes lowest 10% and highest 10% of C<span class="Sub">trough, Tac</span></p>
<p>The protocol-specified target cyclosporine whole blood concentrations (C<span class="Sub">trough,CsA</span>) were 125 to 400 ng/mL for the first three months, and 100 to 300 ng/mL thereafter. The observed median C<span class="Sub">troughs, CsA</span> approximated 280 ng/mL during the first three months and 190 ng/mL from month 4 to month 12.</p>
<p>Patients in both groups started MMF at 1gram twice daily. The MMF dose was reduced to less than 2 grams per day by month 12 in 62% of patients in the tacrolimus/MMF group (Table 22) and in 47% of patients in the cyclosporine/MMF group. Approximately 63% and 55% of these MMF dose reductions were because of adverse reactions in the tacrolimus/MMF group and the cyclosporine/MMF group, respectively [see <span class="Bold">Adverse Reactions (6.1)</span>].</p>
<p><span class="Bold">Table 22. MMF Dose Over Time in the Tacrolimus/MMF Group (Study 2)</span></p>
<table border="1" cellpadding="3" cellspacing="0" width="98%"><tbody class="Headless" align="center">
<tr class="First">
<td rowspan="2" valign="top"><span class="Bold">Time period (Days) </span></td>
<td colspan="3"><span class="Bold">Time-averaged MMF dose (g/day)<span class="Sup">a</span></span></td>
</tr>
<tr>
<td>Less than 2.0</td>
<td>2.0 </td>
<td>Greater than 2.0 </td>
</tr>
<tr>
<td>0 to 30 (N=212) </td>
<td>25% </td>
<td>69% </td>
<td>6% </td>
</tr>
<tr>
<td>0 to 90 (N=212) </td>
<td>41% </td>
<td>53% </td>
<td>6% </td>
</tr>
<tr>
<td>0 to 180 (N=212) </td>
<td>52% </td>
<td>41% </td>
<td>7% </td>
</tr>
<tr>
<td>0 to 365 (N=212) </td>
<td>62% </td>
<td>34% </td>
<td>4% </td>
</tr>
<tr class="Last"><td align="left" colspan="4">Key: Time-averaged MMF dose=(total MMF dose)/(duration of treatment) </td></tr>
</tbody></table>
<p>a) Percentage of patients for each time-averaged MMF dose range during various treatment periods. Two grams per day of time-averaged MMF dose means that MMF dose was not reduced in those patients during the treatment periods.</p>
<p><span class="Bold"></span><span class="Sub"></span><span class="Bold"></span><span class="Bold"></span><span class="Bold"></span><span class="Sub"></span><span class="Bold"></span><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_512f934b-b9b0-4ace-8e47-e0cb63709432"></a><a name="section-13.2"></a><p></p>
<h2><span class="Bold">14.2 Liver Transplantation</span></h2>
<p class="First">The safety and efficacy of tacrolimus-based <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> following orthotopic liver transplantation were assessed in two prospective, randomized, non-blinded multicenter trials. The active control groups were treated with a cyclosporine-based immunosuppressive regimen (CsA/AZA). Both trials used concomitant adrenal corticosteroids as part of the immunosuppressive regimens. These trials compared patient and graft survival rates at 12 months following transplantation.</p>
<p>In one trial, 529 patients were enrolled at 12 clinical sites in the United States; prior to surgery, 263 were randomized to the tacrolimus-based immunosuppressive regimen and 266 to the CsA/AZA. In 10 of the 12 sites, the same CsA/AZA protocol was used, while 2 sites used different control protocols. This trial excluded patients with renal dysfunction, <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">fulminant hepatic failure</span> with Stage IV <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, and cancers; pediatric patients (≤ 12 years old) were allowed.</p>
<p>In the second trial, 545 patients were enrolled at 8 clinical sites in Europe; prior to surgery, 270 were randomized to the tacrolimus-based immunosuppressive regimen and 275 to CsA/AZA. In this trial, each center used its local standard CsA/AZA protocol in the active-control arm. This trial excluded pediatric patients, but did allow enrollment of subjects with renal dysfunction, <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">fulminant hepatic failure</span> in Stage IV <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, and cancers other than primary hepatic with <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>.</p>
<p>One-year patient survival and graft survival in the tacrolimus-based treatment groups were similar to those in the CsA/AZA treatment groups in both trials. The overall 1-year patient survival (CsA/AZA and tacrolimus-based treatment groups combined) was 88% in the U.S. trial and 78% in the European trial. The overall 1-year graft survival (CsA/AZA and tacrolimus-based treatment groups combined) was 81% in the U.S. trial and 73% in the European trial. In both trials, the median time to convert from IV to oral tacrolimus dosing was 2 days. </p>
<p>Although there is a lack of direct correlation between tacrolimus concentrations and drug efficacy, data from clinical trials of liver transplant patients have shown an increasing incidence of adverse reactions with increasing trough blood concentrations. Most patients are stable when trough whole blood concentrations are maintained between 5 to 20 ng/mL. Long-term post-transplant patients often are maintained at the low end of this target range.</p>
<p>Data from the U.S. clinical trial show that the median trough blood concentrations, measured at intervals from the second week to one year post-transplantation ranged from 9.8 ng/mL to 19.4 ng/mL.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ffaafd59-ab63-c1bc-003d-3f7ccb173898"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Heart Transplantation</h2>
<p class="First">Two open-label, randomized, comparative trials evaluated the safety and efficacy of tacrolimus-based and cyclosporinebased <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> in primary orthotopic heart transplantation. In a trial conducted in Europe, 314 patients received a regimen of antibody induction, corticosteroids and azathioprine in combination with tacrolimus or cyclosporine modified for 18 months. In a 3-arm trial conducted in the US, 331 patients received corticosteroids and tacrolimus plus sirolimus, tacrolimus plus mycophenolate mofetil (MMF) or cyclosporine modified plus MMF for 1 year.</p>
<p>In the European trial, patient/graft survival at 18 months post-transplant was similar between treatment arms, 92% in the tacrolimus group and 90% in the cyclosporine group. In the U.S. trial, patient and graft survival at 12 months was similar with 93% survival in the tacrolimus plus MMF group and 86% survival in the cyclosporine modified plus MMF group. In the European trial, the cyclosporine trough concentrations were above the pre-defined target range (i.e., 100 to 200 ng/mL) at Day 122 and beyond in 32 to 68% of the patients in the cyclosporine treatment arm, whereas the tacrolimus trough concentrations were within the pre-defined target range (i.e., 5 to 15 ng/mL) in 74 to 86% of the patients in the tacrolimus treatment arm. Data from this European trial indicate that from 1 week to 3 months post-transplant, approximately 80% of patients maintained trough concentrations between 8 to 20 ng/mL and, from 3 months through 18 months post-transplant, approximately 80% of patients maintained trough concentrations between 6 to18 ng/mL. </p>
<p>The U.S. trial contained a third arm of a combination regimen of sirolimus, 2 mg per day, and full-dose tacrolimus; however, this regimen was associated with increased risk of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing complications, renal function impairment, and insulin-dependent post-transplant <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and is not recommended [see <span class="Bold">Warnings and Precautions (</span><span class="Bold"><a href="#_e6fb816e-da0b-9c41-17be-6995a0dade06">5.12</a></span><span class="Bold">)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HOW_SUPPLIED"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_c3c9f37b-3641-4aa7-46ae-1974fea5dd8c"></a><a name="section-14.1"></a><p></p>
<h2><span class="Bold">16.1 Tacrolimus Capsules </span></h2>
<p class="First">Tacrolimus Capsules USP, 0.5 mg are white to off white powder filled in hard gelatin capsule of size ‘4’, dark yellow opaque cap imprinted with ‘0.5 MG’ and dark yellow opaque body imprinted with ‘RDY 525’using red ink and are supplied in bottles of 30’s, 100’s and 500’s, and unit dose package of 100 (10 x 10).</p>
<p>Bottles of 30                                                                                       NDC 55111-525-30</p>
<p>Bottles of 100                                                                                     NDC 55111-525-01</p>
<p>Bottles of 500                                                                                     NDC 55111-525-05</p>
<p>Unit Dose Package of 100 (10 x 10)                                                   NDC 55111-525-78</p>
<p>Tacrolimus Capsules USP, 1 mg are white to off white powder filled in hard gelatin capsule of size ‘4’, white opaque cap imprinted with ‘1 MG’ and white opaque body imprinted with ‘RDY 526’using red ink and are supplied in bottles of 30’s, 100’s and 500’s, and unit dose package of 100 (10 x 10). </p>
<p>Bottles of 30                                                                                       NDC 55111-526-30</p>
<p>Bottles of 100                                                                                     NDC 55111-526-01</p>
<p>Bottles of 500                                                                                     NDC 55111-526-05</p>
<p>Unit Dose Package of 100 (10 x 10)                                                  NDC 55111-526-78 </p>
<p>Tacrolimus Capsules USP, 5 mg are white to off white powder filled in hard gelatin capsule of size ‘4’, dark grayish red opaque cap imprinted with ‘5 MG’ and dark grayish red  opaque body imprinted with ‘RDY 527’ using white ink and are supplied in bottles of 30’s, 100’s and 500’s, and unit dose package of 100 (10 x 10). </p>
<p>Bottles of 30                                                                                      NDC 55111-527-30</p>
<p>Bottles of 100                                                                                     NDC 55111-527-01</p>
<p>Bottles of 500                                                                                     NDC 55111-527-05</p>
<p>Unit Dose Package of 100 (10 x 10)                                                  NDC 55111-527-78</p>
<p>Note: Tacrolimus capsules are not filled to maximum capsule capacity. Capsule contains labeled amount.</p>
<p><span class="Bold">Store and Dispense</span></p>
<p>Store Tacrolimus capsules at 20°C-25°C (68°F-77°F) [See USP Controlled Room Temperature].</p>
<p><span class="Bold"></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INFORMATION_FOR_PATIENTS"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_e855fe6e-5cda-8a95-91b1-0eb2ca7fd5b2"></a><a name="section-15.1"></a><p></p>
<h2><span class="Bold">17.1 Administration</span></h2>
<p class="First">Advise patients to:</p>
<ul>
<li>Take tacrolimus at the same 12-hour intervals everyday to achieve consistent blood concentrations.</li>
<li>Take tacrolimus consistently either with or without food because the presence and composition of food decreases the bioavailability of tacrolimus.</li>
<li>Not to eat grapefruit or drink grapefruit juice in combination with tacrolimus [see<span class="Bold">Drug Interactions </span><span class="Bold"><a href="#_ae530d6d-766e-6741-d24b-eb43b2d6d14e">(7.2)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_4cd995e6-2e5a-07e5-864b-a37f1ac2f456"></a><a name="section-15.2"></a><p></p>
<h2><span class="Bold">17.2 Development of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and Other Malignancies</span></h2>
<p class="First">Inform patients they are at increased risk of developing <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and other malignancies, particularly of the skin, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. Advise patients to limit exposure to sunlight and ultraviolet (UV) light by wearing protective clothing and use a sunscreen with a high protection factor [see <span class="Bold">Warnings and Precautions (<a href="#_c1430800-6a47-a6a5-a2eb-d70663158c0e">5.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_aa511e63-f2e7-e927-17d3-83aed61aadec"></a><a name="section-15.3"></a><p></p>
<h2><span class="Bold">17.3 Increased Risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></h2>
<p class="First">Inform patients they are at increased risk of developing a variety of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, due to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> and to contact their physician if they develop any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> [see <span class="Bold">Warnings and Precautions (<a href="#_02669390-2e85-f61f-7aac-bc927dd1f4e7">5.3</a>, <a href="#_44b3d223-cdaa-0055-c648-e14294ed0028">5.4</a>, <a href="#_efae5194-9a5b-ac74-3462-14bfa59bb652">5.5</a></span>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_0a10426b-54f3-3595-0f9c-24f66a8ab819"></a><a name="section-15.4"></a><p></p>
<h2><span class="Bold">17.4 New Onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> After Transplant</span></h2>
<p class="First">Inform patients that tacrolimus can cause <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and should be advised to contact their physician if they develop frequent urination, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span> or <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span> [see <span class="Bold">Warnings and Precautions <a href="#_773498b8-5185-3ab8-d970-77c806ec54bd">(5.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2217e53c-cd6a-ce34-d15f-594406ba318e"></a><a name="section-15.5"></a><p></p>
<h2><span class="Bold">17.5 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></span></h2>
<p class="First">Inform patients that tacrolimus can have toxic effects on the kidney that should be monitored. Advise patients to attend all visits and complete all blood tests ordered by their medical team [see <span class="Bold">Warnings and Precautions (<a href="#_646586f3-4314-3d61-f221-3d0e7562ad4f">5.7</a></span>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_da0bac10-18ed-ebbd-e14a-c3a45b7450a8"></a><a name="section-15.6"></a><p></p>
<h2><span class="Bold">17.6 <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></span></h2>
<p class="First">Inform patients that they are at risk of developing adverse neurologic effects including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, altered mental status, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. Advise patients to contact their physician should they develop vision changes, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">deliriums</span>, or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> [see <span class="Bold">Warnings and Precautions <a href="#_6c58d880-0731-32f6-fc2f-48b62ea0f34c">(5.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_66c84a19-67c4-e8ce-30cc-d5bd01bb2605"></a><a name="section-15.7"></a><p></p>
<h2><span class="Bold">17.7 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></h2>
<p class="First">Inform patients that tacrolimus can cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Monitoring of potassium levels may be necessary, especially with concomitant use of other drugs known to cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> [see <span class="Bold">Warnings and Precautions <a href="#_387963e5-2598-e73d-af6c-19d0dd2730e8">(5.9)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_4eb24230-61dc-9a31-6db8-083de0f675de"></a><a name="section-15.8"></a><p></p>
<h2><span class="Bold">17.8 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></h2>
<p class="First">Inform patients that tacrolimus can cause high blood pressure which may require treatment with anti-hypertensive therapy [see <span class="Bold">Warnings and Precautions <a href="#_705070f6-9650-af7d-b658-b66fead6566c">(5.10)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_cb42410a-3d66-3487-c95c-b3b33ac2b066"></a><a name="section-15.9"></a><p></p>
<h2><span class="Bold">17.9 Drug Interactions</span></h2>
<p class="First">Instruct patients to tell their health care providers when they start or stop taking all the medicines, including prescription medicines and non-prescription medicines, natural or herbal remedies, nutritional supplements and vitamins [see <span class="Bold">Drug Interactions <a href="#DRUG_INTERACTIONS">(7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_86c19011-ca09-72cb-9b01-97cc545e4779"></a><a name="section-15.10"></a><p></p>
<h2><span class="Bold">17.10 Pregnant Women and Nursing Mothers</span></h2>
<p class="First">Instruct patients to tell their healthcare provider if they plan to become pregnant or breast-feed their infant [see <span class="Bold">Use in Specific Populations (<a href="#PREGNANCY">8.1,</a><a href="#NURSING_MOTHERS">8.3</a>)</span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_d2634aad-fa6e-1027-c636-1753c1e9789e"></a><a name="section-15.11"></a><p></p>
<h2><span class="Bold">17.11 Immunizations</span></h2>
<p class="First">Inform patients that tacrolimus can interfere with the usual response to immunizations and that they should avoid live vaccines [see <span class="Bold">Warnings and Precautions <a href="#_fef74a58-2fff-8264-0a04-7917ca25611d">(5.16)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_0f1cb6cb-ef41-6f53-d32a-4e0cd1ada540"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Patient Information</span><span class="Bold"> </span><span class="Bold"></span></p>
<p><span class="Bold">Tacrolimus Capsules USP</span><span class="Bold"> </span></p>
<p>Read this Patient Information before you start taking tacrolimus capsules and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. <span class="Bold"></span></p>
<p><span class="Bold">What is the most important information I should know about tacrolimus capsules?</span><span class="Bold"></span></p>
<p><span class="Bold">Tacrolimus capsules can cause serious side effects, including:</span><span class="Bold"> </span></p>
<p><span class="Bold">1. </span><span class="Bold"></span><span class="Bold">Increased risk of cancer. </span>People who take tacrolimus capsules have an increased risk of getting some kinds of cancer, including skin and lymph gland cancer (<span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>).<span class="Bold"></span><span class="Bold"></span></p>
<p><span class="Bold">2. </span><span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </span>Tacrolimus capsules is a medicine that affects your immune system. Tacrolimus capsules can lower the ability of your immune system to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can happen in people receiving tacrolimus capsules that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Bold">Call your doctor right away if you have symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span></li>
<li>weats or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or flu-like symptoms</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li>warm, red, or painful areas on your skin <span class="Bold"></span>
</li>
</ul>
<p><span class="Bold">What are tacrolimus capsules?</span></p>
<p>Tacrolimus capsules are a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney, liver, or heart transplant and tacrolimus capsules are not for use with medicines called cyclosporines (Gengraf<span class="Sup">®</span>, Neoral<span class="Sup">®</span>, and Sandimune<span class="Sup">®</span>).</p>
<p>Tacrolimus capsules are not for use with a medicine called sirolimus (Rapamune<span class="Sup">®</span>) in people who have had a liver or heart transplants. </p>
<p>It is not known if tacrolimus capsules are safe and effective when used with sirolimus in people who have had kidney transplants. </p>
<p>It is not known if tacrolimus capsules are safe and effective in children who have had a kidney or heart transplants.</p>
<p><span class="Bold">Who should not take tacrolimus capsules?</span><span class="Bold"></span></p>
<p><span class="Bold">Do not take tacrolimus capsules if you </span>are allergic to tacrolimus or any of the ingredients in tacrolimus capsules. See the end of this leaflet for a complete list of ingredients in tacrolimus capsules.<span class="Bold"> </span><span class="Bold"></span></p>
<p><span class="Bold">What should I tell my doctor before taking tacrolimus capsules?</span><span class="Bold"></span></p>
<p><span class="Bold">Before you take tacrolimus capsules, tell your doctor if you:</span></p>
<ul>
<li>plan to receive any live vaccines </li>
<li>have or have had liver, kidney or heart problems</li>
<li>are pregnant or plan to become pregnant. Tacrolimus capsules may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</li>
<li>Are breastfeeding or plan to breastfeed. Tacrolimus capsules can pass into your breast milk. You and your doctor should decide if you will take tacrolimus capsules or breastfeed. You should not do both. </li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins, and herbal supplements. </p>
<p>Especially tell your doctor if you take:</p>
<ul>
<li>cyclosporine (Gengraf<span class="Sup">®</span>, Neoral<span class="Sup">®</span>, and Sandimune<span class="Sup">®</span>)</li>
<li>sirolimus (Rapamune<span class="Sup">®</span>)</li>
<li>nelfinavir (Viracept<span class="Sup">®</span>) </li>
<li>telaprevir (Incivek<span class="Sup">TM</span>) </li>
<li>boceprevir (Victrelis<span class="Sup">TM</span>) </li>
<li>amiodarone (Cordarone<span class="Sup">TM</span>, Nexterone<span class="Sup">TM</span>, Pacerone<span class="Sup">TM</span>)</li>
</ul>
<p>Ask your doctor or pharmacist if you are not sure if you take any of the medicines listed above. Tacrolimus capsules may affect the way other medicines work, and other medicines may affect how tacrolimus capsules works. Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take tacrolimus capsules?</span></p>
<ul>
<li>
<span class="Bold"></span>Take tacrolimus capsules exactly as your doctor tells you to take it.</li>
<li>Your doctor will tell you how many tacrolimus capsules to take and when to take them.</li>
<li>Your doctor may change your tacrolimus capsules dose if needed. <span class="Bold">Do not </span>stop taking or change your dose of tacrolimus capsules without talking to your doctor.</li>
<li>Take tacrolimus capsules with or without food.</li>
<li>Take tacrolimus capsules the same way everyday. For example, if you choose to take tacrolimus capsules with food, you should always take tacrolimus capsules with food.</li>
<li>Take tacrolimus capsules at the same time each day. For example, if you take your first dose at 7: 00 a.m. you should take your second dose at 7:00 p.m<ul><li>Taking tacrolimus capsules at the same time each day helps to keep enough medicine in your body to give your transplanted organ the around-the-clock medicine it needs.</li></ul>
</li>
<li>
<span class="Bold">Do not </span>eat grapefruit or drink grapefruit juice while taking tacrolimus capsules.</li>
<li>If you take too much tacrolimus capsules, call your doctor or go to the nearest hospital emergency room right away. <span class="Bold"></span>
</li>
</ul>
<p><span class="Bold">What should I avoid while taking tacrolimus capsules?</span></p>
<ul><li>While you take tacrolimus capsules you should not receive any live vaccines such as:<ul>
<li>flu vaccine through your nose</li>
<li><span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span></li>
<li><span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span></li>
<li><span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span></li>
<li><span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span> by mouth</li>
<li>BCG (TB vaccine)</li>
<li><span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">yellow fever</span></li>
<li>chicken pox (<span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span></li>
</ul>
</li></ul>
<ul><li>Avoid exposure to sunlight and UV light such as tanning machines. Wear protective clothing and use a sunscreen.</li></ul>
<p><span class="Bold">What are the possible side effects of tacrolimus capsules?</span><span class="Bold"></span></p>
<p><span class="Bold">Tacrolimus capsules may cause serious side effects, including:</span></p>
<ul>
<li>
<span class="Bold"></span><span class="Bold">See “What is the most important information I should know about tacrolimus capsules?</span>
</li>
<li>
<span class="Bold">?</span><span class="Bold">high blood sugar (<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>). </span>Your doctor may do certain tests to check for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> while you take tacrolimus capsules. Call your doctor right away if you have:<ul>
<li>frequent urination</li>
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span> or <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li>loss of appetite</li>
<li>fruity smell on your breath</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or stomach pain </li>
</ul>
</li>
<li>
<span class="Bold">kidney problems. </span>Your doctor may do certain tests to check your kidney function while you take tacrolimus capsules.<span class="Bold"></span>
</li>
<li>
<span class="Bold">nervous system problems. </span>Call your doctor right away if you get any of these symptoms while taking tacrolimus capsules. These could be signs of a serious nervous system problem:<ul>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></li>
<li>muscle <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span></li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
<li>vision changes</li>
</ul>
<span class="Bold"></span>
</li>
<li>
<span class="Bold">high levels of potassium in your blood. </span>Your doctor may do certain tests to check your potassium level while you take tacrolimus capsules.</li>
<li>
<span class="Bold">high blood pressure. </span>Your doctor will monitor your blood pressure while you take tacrolimus capsules.<span class="Bold"> </span>
</li>
<li>
<span class="Bold">heart problems (myocardial <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>). </span>Tell your doctor right away if you get any of these symptoms of heart problems while taking tacrolimus capsules: <ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li>feel lightheaded</li>
<li>feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span></li>
</ul>
</li>
</ul>
<p><span class="Bold">The most common side effects of tacrolimus capsules in people receiving kidney transplant are:</span></p>
<ul>
<li>
<span class="Bold"></span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> of the body)</li>
<li>high blood pressure</li>
<li>kidney problems</li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>trouble sleeping</li>
<li>nauseal</li>
<li>ow levels of phosphate in your blood</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the hands, ankles, or legs</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>high levels of fat in your blood</li>
<li>high levels of potassium in your blood</li>
<li>low red blood cell count (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) </li>
</ul>
<p><span class="Bold">The most common side effects of tacrolimus capsules in people receiving liver transplants are:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> of the body <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>kidney problems</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>trouble sleeping</li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your hands or feet</li>
<li><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li>high levels of potassium in the blood</li>
<li>low levels of magnesium in the blood<span class="Bold"> </span>
</li>
</ul>
<p><span class="Bold">The most common side effects of tacrolimus for heart transplant patients are: </span></p>
<ul>
<li>kidney problems</li>
<li>high blood pressure</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of tacrolimus capsules. For more information, ask your doctor or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <span class="Bold"></span></p>
<p><span class="Bold">How should I store tacrolimus capsules</span><span class="Bold">?</span></p>
<p><span class="Bold"></span>Store Tacrolimus capsules at 20°C-25°C (68°F-77°F) </p>
<p>Safely throw away medicine that is out of date or no longer needed.<span class="Bold"></span></p>
<p><span class="Bold">Keep tacrolimus capsules and all medicines out of reach of children.</span><span class="Bold"> </span><span class="Bold"></span></p>
<p><span class="Bold">General information about the safe and effective use of tacrolimus capsules</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use tacrolimus capsules for a condition for which it was not prescribed. Do not give tacrolimus capsules to other people, even if they have the same symptoms that you have. It may harm them. <span class="Bold"></span></p>
<p><span class="Bold">How does tacrolimus capsules protect my new organ</span><span class="Bold">?</span></p>
<p>The body’s immune system protects the body against anything that it does not recognize as part of the body. For example, when the immune system detects a virus or bacteria it tries to get rid of it to prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. When a person has a liver, kidney or heart transplant, the immune system does not recognize the new organ as a part of the body and tries to get rid of it, too. This is called “rejection?. Tacrolimus capsules protects your new organ by slowing down the body’s immune system. </p>
<p>This Patient Information leaflet summarizes the most important information about tacrolimus capsules. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about tacrolimus capsules that is written for health professionals. </p>
<p>For more information, <a href="http://www.astellas.com/us%20or%20call%201-800-727-7003">call</a> 1-888-375-3784. <span class="Bold"></span></p>
<p><span class="Bold">What are the ingredients in tacrolimus capsules?</span></p>
<p>Active ingredient: tacrolimus</p>
<p>Inactive ingredients: croscarmellose sodium, lactose monohydrate and magnesium stearate. The 0.5 mg capsule shell contains gelatin, iron oxide red, iron oxide yellow and titanium dioxide, the 1 mg capsule shell contains gelatin and titanium dioxide and the 5 mg capsule shell contains gelatin, iron oxide red, iron oxide black, and titanium dioxide. </p>
<p><span class="Bold">This Patient Information has been approved by the U.S. Food and Drug Administration.</span><span class="Bold"> </span></p>
<p>To reorder additional Patient Information Sheets, Contact Dr. Reddy's Customer Service at 1-866-733-3952. <span class="Italics Underline"> </span></p>
<p><span class="Italics Underline"></span>Rx Only</p>
<p>Manufactured by<span class="Bold"></span></p>
<p><span class="Bold">Dr. Reddy’s Laboratories Limited</span></p>
<p>Bachupally - 500 090 INDIA</p>
<p>Revised: 0615</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_6bed8424-d639-399b-8cda-6dcee9871152"></a><a name="section-17"></a><p></p>
<h1>Package Label. Prinicipal Display Panel</h1>
<p class="First">Tacrolimus Capsules, 0.5 mg - Container Label.</p>
<p></p>
<p><img alt="Container1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=Container1.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_7cf57f93-bed3-39d5-416b-ef95739659c4"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First">Tacrolimus Capsules, 0.5 mg - Container Carton Label</p>
<p></p>
<p><img alt="ContainerCarton1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=ContainerCarton1.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_ea843ec4-d65e-5909-96f5-0be8928603d2"></a><a name="section-19"></a><p></p>
<h1></h1>
<p class="First">Tacrolimus Capsules, 0.5 mg - <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton Label</p>
<p><img alt="BlisterCarton1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=BlisterCarton1.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_1bf150cc-6976-25c3-e5fd-afbe0d13d475"></a><a name="section-20"></a><p></p>
<h1></h1>
<p class="First">Tacrolimus Capsules, 1 mg - Container Label</p>
<p></p>
<p><img alt="Container2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=Container2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_12640ad6-8d1d-78ce-8933-6a534f11a391"></a><a name="section-21"></a><p></p>
<h1></h1>
<p class="First">Tacrolimus Capsules, 1 mg - Container Carton Label</p>
<p></p>
<p><img alt="ContainerCarton2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=ContainerCarton2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_d5a9ae73-b762-4ffd-09b5-eef7ce95dc2a"></a><a name="section-22"></a><p></p>
<h1></h1>
<p class="First">Tacrolimus Capsules, 1 mg - <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton Label</p>
<p></p>
<p><img alt="BlisterCarton2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=BlisterCarton2.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_50127c4c-13a4-b755-13e0-a16b1d4b9021"></a><a name="section-23"></a><p></p>
<h1></h1>
<p class="First">Tacrolimus Capsules, 5 mg - Container Label</p>
<p></p>
<p><img alt="Container3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=Container3.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_a61ee478-a4a3-1458-b17f-d5d7552f4763"></a><a name="section-24"></a><p></p>
<h1></h1>
<p class="First">Tacrolimus Capsules, 5 mg - Container Carton Label</p>
<p></p>
<p><img alt="ContainerCarton3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=ContainerCarton3.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_b09d95f8-0423-0b04-72a1-339371e9f577"></a><a name="section-25"></a><p></p>
<h1></h1>
<p class="First">Tacrolimus Capsules, 5 mg - <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Carton Label</p>
<p></p>
<p><img alt="BlisterCarton3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=61dee012-43af-0e9a-3843-9b9b91e022c4&amp;name=BlisterCarton3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TACROLIMUS 		
					</strong><br><span class="contentTableReg">tacrolimus capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55111-525</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tacrolimus</strong> (tacrolimus anhydrous) </td>
<td class="formItem">tacrolimus anhydrous</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (dark yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">0;5MG;RDY525</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55111-525-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55111-525-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55111-525-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55111-525-78</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55111-525-79</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090509</td>
<td class="formItem">05/14/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TACROLIMUS 		
					</strong><br><span class="contentTableReg">tacrolimus capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55111-526</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tacrolimus</strong> (tacrolimus anhydrous) </td>
<td class="formItem">tacrolimus anhydrous</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1MG;RDY526</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55111-526-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55111-526-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55111-526-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55111-526-78</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55111-526-79</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090509</td>
<td class="formItem">05/14/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TACROLIMUS 		
					</strong><br><span class="contentTableReg">tacrolimus capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55111-527</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tacrolimus</strong> (tacrolimus anhydrous) </td>
<td class="formItem">tacrolimus anhydrous</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (dark grayish red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">5MG;RDY527</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55111-527-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55111-527-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55111-527-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55111-527-78</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55111-527-79</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090509</td>
<td class="formItem">05/14/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dr. Reddy's Laboratories Limited
							(650562841)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dr. Reddy's Laboratories Limited - FTO3</td>
<td class="formItem"></td>
<td class="formItem">918608162</td>
<td class="formItem">analysis(55111-525, 55111-526, 55111-527), manufacture(55111-525, 55111-526, 55111-527)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>030e3b98-39ad-2017-06ae-4d7186f9e14b</div>
<div>Set id: 61dee012-43af-0e9a-3843-9b9b91e022c4</div>
<div>Version: 7</div>
<div>Effective Time: 20150622</div>
</div>
</div> <div class="DistributorName">Dr. Reddy's Laboratories Limited</div></p>
</body></html>
